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ABSTRACT 20 
 21 
Human cytomegalovirus (HCMV) extensively modulates host cells, downregulating >900 22 
human proteins during viral replication and degrading ≥133 proteins shortly after infection. 23 
The mechanism of degradation of most host proteins remains unresolved, and the functions of 24 
many viral proteins are incompletely characterised. We performed a mass spectrometry-based 25 
interactome analysis of 169 tagged, stably-expressed canonical strain Merlin HCMV proteins, 26 
and two non-canonical HCMV proteins, in infected cells. This identified a network of >3,400 27 
virus-host and >150 virus-virus protein interactions, providing insights into functions for 28 
multiple viral genes. Domain analysis predicted binding of the viral UL25 protein to SH3 29 
domains of NCK Adaptor Protein-1. Viral interacting proteins were identified for 31/133 30 
degraded host targets. Finally, the uncharacterised, non-canonical ORFL147C protein was 31 
found to interact with elements of the mRNA splicing machinery, and a mutational study 32 
suggested its importance in viral replication. The interactome data will be important for 33 
future studies of herpesvirus infection. 34 
 35 
 36 
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INTRODUCTION 40 
 41 
Human cytomegalovirus (HCMV) persistently infects the majority of the worldwide 42 
population (Mocarski et al., 2013). Following primary infection under the control of a healthy 43 
immune system, a latent infection is established that persists lifelong (Reeves et al., 2005). In 44 
immunocompromised individuals, particularly transplant recipients and AIDS patients, virus 45 
reactivated from latency to induce lytic infection is capable of affecting almost any organ 46 
system and causing serious disease (Nichols et al., 2002). HCMV infection in utero is a 47 
leading cause of deafness and intellectual disability in newborns, affecting ~1/200 48 
pregnancies (Mocarski et al., 2013). 49 
 50 
Small-molecule disruption of critical virus-virus or virus-host protein interactions could 51 
provide novel therapeutic strategies. Indeed, disruption of interactions between antiviral 52 
restriction factors (ARFs) and viral antagonists can facilitate endogenous inhibition of 53 
infection (Nathans et al., 2008). Systematic characterisation of all viral protein interactions 54 
thus has important implications for antiviral therapy, and is particularly important for HCMV, 55 
for which only a few drugs are available. 56 
 57 
HCMV encodes 170 canonical protein-coding genes (Gatherer et al., 2011), and a substantial 58 
number of non-canonical open reading frames (ORFs) that potentially encode additional 59 
proteins have been identified by ribosomal footprinting and proteomics (Nightingale et al., 60 
2018; Stern-Ginossar et al., 2012). During productive infection in vitro, HCMV gene 61 
expression is conventionally divided into immediate-early, early and late phases over a 62 
replication cycle lasting ~96 hours. Five temporal classes of viral protein expression have 63 
been defined by measuring viral protein profiles over time (Weekes et al., 2014). Latent 64 
infection with HCMV occurs in a restricted range of cell types, and may involve a somewhat 65 
more limited range of viral gene expression (Goodrum et al., 2018; Schwartz et al., 2019). 66 
However, at least some viral proteins function similarly during both productive infection and 67 
latency. For example, UL138, which plays roles in the establishment and maintenance of 68 
latent infection, downregulates Multidrug Resistance-Associated Protein 1 (MRP1) during 69 
both phases of infection (Weekes et al., 2013; Weekes et al., 2014). 70 
 71 
The functions of many canonical HCMV proteins remain poorly understood, and it is not yet 72 
clear how many, if any, non-canonical ORFs encode functional polypeptides. We have shown 73 
previously that >900 host proteins are downregulated >3 fold over the course of HCMV 74 
infection, with 133 proteins degraded in the proteasome or lysosome during the early phase 75 
(Nightingale et al., 2018; Weekes et al., 2014). However, it is not yet known which viral 76 
factors target these proteins, and certain proteins, including MHC class I molecules and 77 
natural killer cell ligands, can be targeted by more than one viral factor (Fielding et al., 2014; 78 
Hsu et al., 2015; van der Wal et al., 2002; Wilkinson et al., 2008). 79 
 80 
Here, an examination of each canonical and a subset of non-canonical HCMV proteins in 81 
infected cells revealed an extensive network of >3400 high confidence virus-host and >150 82 
virus-virus interactions. This provided insights into the functions of multiple uncharacterised 83 
or partly characterised viral proteins. The data enabled identification of individual viral 84 
factors that target 31 host proteins for degradation. Novel interactions between selected viral 85 
and host protein domains were also tested experimentally. In addition, the study provided the 86 
first evidence for a functional role for a non-canonical HCMV ORF in viral infection. The 87 
extensive interactome data generated in this study predicts viral proteins important in key 88 
cellular pathways, and may lead to the development of new antiviral therapeutics. 89 
 90 
 91 
 92 
 93 
 94 
 95 
 96 
 97 
 98 
  99 
RESULTS 100 
 101 
Construction of the HCMV-host interactome 102 
 103 
To build a global picture of all HCMV virus-host and virus-virus protein interactions, 170 104 
stable cell lines were generated from immortalised primary human fetal foreskin fibroblasts 105 
(HFFF-TERTs), each expressing a single, canonical HCMV ORF with a C-terminal V5 tag to 106 
facilitate immunoprecipitation (IP). Two non-canonical ORFs, ORFL147C and ORFS343C, 107 
were also included on the basis of either high or low expression respectively, relative to all 108 
other viral ORFs detected previously by proteomics (Figure 1 – Figure Supplement 1A, 109 
Supplementary File 1A) (Fielding et al., 2017; Weekes et al., 2014). Prior to profiling by IP-110 
mass spectrometry (IP-MS), expression of each tagged viral ‘bait’ protein was validated by 111 
immunoblotting (IB), MS or RT-qPCR, apart from UL136 which could not be detected by 112 
any method (Figure 1 – Figure Supplement 1B, Supplementary File 1B). To examine the 113 
full range of virus-virus interactions in addition to virus-host interactions, IP was performed 114 
in cells infected with Merlin strain HCMV at multiplicity of infection (MOI) of 2 for 60 h. 115 
Merlin contains a full length genome and expresses all HCMV genes apart from UL128 and 116 
RL13. All detectable viral proteins are expressed at 60 h post-infection (PI) with this strain 117 
(Weekes et al., 2014) (Figure 1 – Figure Supplement 1E). A schematic and details of the 118 
IP-MS strategy are shown in Figure 1. 119 
 120 
For HCMV UL120 and UL142, no interacting proteins passed the stringent filters employed. 121 
For seven further proteins, only the bait itself passed filtering, leaving 162 viral baits with ≥1 122 
HCIP. In total, 3572 interactions were detected across all 162 baits, with a range of 1-174 123 
interactions per bait, reflecting a scale-free degree distribution typical of protein interaction 124 
networks. The median number of interactions per bait was 9, similar to previously observed 125 
in the Bioplex 2.0 human interactome (Huttlin et al., 2015) (Materials and Methods; 126 
Supplementary File 2A, Figure 1 – Figure Supplement 2A). Data were validated from 127 
previously reported virus-virus and virus-host interactions described in BioGRID, IntAct, 128 
Uniprot, MINT and Virus Mentha (Figure 1 – Figure Supplement 2B, Supplementary 129 
Files 2-3) (Calderone et al., 2015; Chatr-Aryamontri et al., 2013; Licata et al., 2012; Orchard 130 
et al., 2014). 131 
 132 
Systematic analysis of viral protein function 133 
 134 
Systematic analysis of protein interactions can improve understanding of viral protein 135 
function. To analyse the functions of all viral proteins simultaneously, DAVID software 136 
(Huang da et al., 2009) was employed to determine which pathways were enriched amongst 137 
the 3416 human proteins that interacted with viral baits (Figure 2 centre, Figure 2 – Figure 138 
Supplement 1, Supplementary File 4A-B). 139 
 140 
Nucleosome remodeling (NuRD) complex components were significantly enriched among 141 
HCMV-interacting proteins. The NuRD complex plays major roles in cellular chromatin 142 
remodeling, and is known to be co-opted by HCMV UL29 and UL38 to enhance expression 143 
of immediate-early genes (Savaryn et al., 2013; Terhune et al., 2010). The interaction of 144 
UL29 and UL38 in a complex with all components of NuRD was confirmed, in addition to 145 
p53 (Savaryn et al., 2013). UL29 was also found to interact with multiple human proteins that 146 
function in histone deacetylation, which had not been observed previously (Figure 2). 147 
 148 
UL87, UL79, UL91 and UL95 are essential for viral replication and necessary for 149 
transcriptional activation of viral genes expressed with ‘true late’ kinetics. UL92 has a similar 150 
function, and it has been suggested that these five proteins may form one or more complexes 151 
that modulate RNA polymerase II activity (Isomura et al., 2011; Omoto et al., 2013, 2014). 152 
Interactome data confirmed that UL87 interacted with UL79, UL91 and UL95 but did not 153 
detect an interaction with UL92. This latter observation, and in fact the lack of identification 154 
of any viral-viral UL92 interactions may be explained by our finding that UL92 was one of 155 
the two least abundantly expressed viral proteins during HCMV infection (Supplementary 156 
File 1A, bottom). UL87 also interacted with all 12 components of the RNA polymerase II 157 
(RPII) complex and the associated protein RPII Associated Protein 2 (RPAP2) (Figure 2). 158 
The UL87-RPII interaction was anticipated by analogy to the orthologous RPII-interacting 159 
Epstein-Barr virus protein BcRF1, but had not previously been demonstrated. Interaction of 160 
UL87, UL95 and UL79 with the UL97 protein kinase was also novel. 161 
 162 
Collectively, these confirmatory data indicate that the HCMV interactome has the power to 163 
predict new functions for uncharacterised or partly characterised viral proteins, particularly 164 
where a bait interacts with multiple protein components of the same pathway. For example, 165 
UL72 is a temporal protein profile 3 (Tp3)-class HCMV protein derived from deoxyuridine 166 
5'-triphosphate nucleotidohydrolase (dUTPase) in other herpesviruses, but lacks dUTPase 167 
activity (Caposio et al., 2004; McGeehan et al., 2001). UL72 interacted with all 10 168 
components of the CCR4-NOT (carbon catabolite repressor 4-negative on TATA) complex, 169 
which is a key regulator of gene expression from production of mRNAs in the nucleus to 170 
their degradation in the cytoplasm (Yi et al., 2018). The interaction between UL72 and 171 
CNOT2/CNOT7 was confirmed by co-IP (Figures 3A-B). It remains to be determined how 172 
UL72 modulates CCR4-NOT function. 173 
 174 
The hitherto uncharacterised viral UL145 protein is known to recruit the Cullin 4 E3 ligase 175 
scaffold and associated adaptor proteins, and to degrade helicase-like transcription factor 176 
(HLTF) (Nightingale et al., 2018). Interactome data suggested that all human proteins 177 
interacting with UL145 and the paralogous RL1 were part of the ubiquitin conjugation 178 
pathway (Supplementary File 2, Supplementary File 4), and furthermore that RL1 179 
interacted with Cullin 4 (CUL4, Figure 2). The interaction with CUL4A was validated by co-180 
IP (Figure 3C). Proteins that are degraded after binding RL1/CUL4 still require 181 
identification; it is possible that their abundance after degradation may have been insufficient 182 
to enable identification in this study. Multiple other HCMV proteins additionally interacted 183 
with elements of the ubiquitin transfer or conjugation pathways, including the inhibitor of 184 
apoptosis UL36, which bound the Cullin 1 scaffold, E3 ligase UBR5, and F-box component 185 
FBOX3. Similarly, DNA helicase/primase component UL102 interacted with E3 ligase 186 
RNF114 and E2 conjugating enzyme UBE2L6 (Figure 2 and Supplementary File 2). 187 
 188 
The tegument protein UL71 has an essential function in the final steps of secondary 189 
envelopment leading to infectious viral particles, but is expressed with Tp3 kinetics, 190 
suggesting the possibility of a role earlier during infection (Dietz et al., 2018; Meissner et al., 191 
2012; Weekes et al., 2014). UL71 interacted with multiple interferon-stimulated proteins 192 
(Figure 3D), including TRIM22, which restricts replication of HIV-1, influenza A and 193 
hepatitis B and C viruses (Lian et al., 2017). The UL71-TRIM22 interaction validated by co-194 
IP, suggesting that investigation of a putative innate immune role for UL71 will be important 195 
(Figure 3E). 196 
 197 
In addition to characterising baits that interacted with multiple members of individual cellular 198 
pathways, an alternative approach identified pathways whose members interacted 199 
predominantly with single baits (Figure 2 – Figure Supplement 1). The US28 G-protein 200 
coupled receptor (GPCR) functions in both lytic and latent HCMV infection via constitutive 201 
signaling to activate distinct intracellular pathways (Krishna et al., 2018). Here, US28 202 
interacted with all quantified members of thick filament/muscle myosin complexes, namely 203 
myosin heavy and light chain components, a myosin binding protein and titin. This suggests 204 
an unanticipated role for US28 in processes such as regulation of the actin cytoskeleton or 205 
cytoskeletal remodeling (Wang et al., 2018). Other viral proteins may have novel functions 206 
modulating vesicular transport. For example, the US27 GPCR interacted with multiple 207 
components of the SNARE complex, whose primary function is to mediate vesicle fusion 208 
(Han et al., 2017). Envelope glycoprotein UL132 interacted with the AP-2 adaptor complex, 209 
which functions in clathrin-mediated endocytosis (Figure 2 – Figure Supplement 1) 210 
(Collins et al., 2002). 211 
 212 
To gain further insights into temporal regulation of protein-protein interactions, we 213 
determined which functions were enriched amongst human HCIPs for each of the five 214 
temporal classes of HCMV bait (Weekes et al., 2014). A clear relation to functions required 215 
at different stages of the viral life-cycle was observed (Figure 2 – Figure Supplement 2A, 216 
Supplementary File 4C). For example, Tp1 and Tp2 protein HCIPs were enriched in NuRD 217 
complex members, proteins involved in histone deacetylation and proteins with SANT 218 
domains (which function in chromatin remodelling). Tp3 HCIPs were enriched in functions 219 
required for viral genomic replication and immune evasion, whilst Tp5 HCIPs were directed 220 
at intracellular trafficking and secretion (Figure 2 – Figure Supplement 2A). For viral-viral 221 
protein interactions, two patterns emerged – (a) interaction of viral proteins within the same 222 
temporal class, or between adjacent classes; (b) interaction of proteins from the largest class 223 
(Tp5) with members of each of the five classes (Figure 2 – Figure Supplement 2B, 224 
Supplementary File 4D). For example, Tp1 and Tp2 class proteins UL29 and UL38 225 
interacted, as previously reported (Supplementary File 3, Figure 2). Tp1-class tegument 226 
proteins US23 and US24 interacted. The majority of Tp5 interactions were with other Tp5 227 
proteins, 15/37 of which were tegument-tegument, capsid-capsid or tegument-capsid protein 228 
interactions (Figure 2 – Figure Supplement 2B). Certain interactions between proteins in 229 
different temporal classes have also been reported; for example, between the Tp5 DNA 230 
polymerase accessory protein UL44 and Tp2 DNA polymerase UL54. Clearly, other novel 231 
interactions also exist between quite distinctly expressed proteins, for example between the 232 
functionally unknown Tp2-class membrane protein UL14 and two Tp5-class proteins: 233 
membrane protein UL121 and envelope glycoprotein UL4.   234 
 235 
 236 
 237 
 238 
Association between functional domains revealed by protein-protein interactions 239 
 240 
Certain domains perform related functions within diverse proteins, often via interactions with 241 
complementary structures. The function and interaction(s) of these domains can be predicted 242 
by analysing interactions between their parent proteins (Finn et al., 2014; Huttlin et al., 243 
2015). Although domains that co-occur frequently do not necessarily interact directly, these 244 
associations can nevertheless provide insights into domain biology. 245 
 246 
By mapping Pfam domains to every bait and prey protein in the interactome, it was possible 247 
to identify domain pairs that interact with unusual frequency (Figure 4A) (Finn et al., 2014). 248 
This correctly predicted that HCMV glycoprotein UL141 interacts with TNFR cysteine-rich 249 
domains (TNFR c6), which has been demonstrated for TNFRSF10B and predicted for 250 
TNFRSF10A (Nemcovicova et al., 2013). UL141 also interacted with TNFRSF10D as 251 
reported (Smith et al., 2013) and was found to interact with TNFRSF1A, suggesting that 252 
these interactions may also occur via the TNFR c6 domain (Figure 4A, Supplementary File 253 
5B). 254 
 255 
Domain analysis predicted that certain Herpes pp85 proteins interact with host SH3 domains. 256 
Underlying interactome data suggested that the viral tegument pp85 phosphoprotein UL25 257 
interacted with SH3 domain-containing proteins NCK1 (Non-catalytic region of protein 258 
tyrosine kinase 1) and NCK2. Additionally, UL25 interacted with two other human proteins 259 
and the viral tegument protein UL26. UL26 had more diverse targets, including NCK2 but 260 
not NCK1 (Figures 4A-B, Supplementary File 2, Supplementary File 5). 261 
 262 
 263 
SH3 domains are known to interact with proline-rich regions (Kurochkina et al., 2013). UL25 264 
has a proline-rich C-terminus, and NCK1 has three N-terminal SH3 regions. A series of 265 
mutations or truncations (Figure 4C) suggested that the UL25 C-terminus interacts with the 266 
first NCK1 SH3 domain alone, validating and extending the prediction from domain 267 
association analysis (Figure 4D). 268 
 269 
NCK1 is a multifunctional cytoplasmic adaptor protein with known roles in signal 270 
transduction from receptor tyrosine kinases, cytoplasmic remodeling via regulation of actin 271 
polymerization, apoptosis and the DNA damage response (Buvall et al., 2013; Keyvani Chahi 272 
et al., 2016; Ngoenkam et al., 2014). Interaction of UL25 with NCK1 may thus fulfill a 273 
variety of functions. One possibility may include inhibition of immune synapse formation. 274 
HCMV UL135 is known to dispel association between F-actin filaments in target cells and 275 
the immune synapse (Stanton et al., 2014). UL25 might regulate actin polymerisation in a 276 
complementary manner in order to achieve a similar aim. 277 
 278 
Viral proteins that degrade cellular prey 279 
 280 
We previously described a multiplexed approach for discovering proteins that have innate 281 
immune function on the basis of their active degradation by the proteasome or lysosome 282 
during the early phase of HCMV infection. Using three orthogonal proteomic/transcriptomic 283 
screens to quantify protein degradation, 133 proteins were shown to be degraded in the 284 
proteasome or lysosome during early phase infection, which were enriched in novel antiviral 285 
restriction factors (Nightingale et al., 2018). To facilitate the mapping of viral gene functions, 286 
a final screen employed a panel of HCMV mutants, each deleted in contiguous gene blocks 287 
dispensable for virus replication in vitro. However, this screen did not confidently identify 288 
the genetic loci that targeted 121/133 degraded proteins. Furthermore, even for 12/133 289 
confidently identified loci, characterization of which individual viral genes degraded cellular 290 
targets often proved arduous. For example, to identify UL145 as the gene within the UL133-291 
UL150 block that targeted HLTF to the proteasome, 19 single viral gene deletion mutants 292 
required testing (Nightingale et al., 2018). 293 
 294 
Interactome data revealed viral baits for 31/133 degraded prey (Supplementary File 6). The 295 
ubiquitin E3 ligase ITCH (Itchy E3 Ubiquitin Protein Ligase) is known to be targeted for 296 
degradation by viral UL42 (Koshizuka et al., 2016). In addition to ITCH, UL42 interacted 297 
with Neural Precursor Cell Expressed, Developmentally Down-Regulated 4 (NEDD4)- 298 
family E3 ligases NEDD4 and NEDD4-like (NEDD4L), which were degraded during early 299 
HCMV infection (Figures 5A-B) (Nightingale et al., 2018). These interactions were 300 
validated by co-IP using both C- and N-terminally V5 tagged UL42, and UL42 was shown to 301 
be sufficient for degradation of NEDD4 (Figures 5D-E, Figure 5 – Figure Supplement 1). 302 
UL42 protein has not been detected in any of our previous proteomic studies (Fielding et al., 303 
2017; Nightingale et al., 2018; Weekes et al., 2014), however UL42 transcript was quantified 304 
by Stern-Ginossar et al (Stern-Ginossar et al., 2012). Although expression of this transcript 305 
peaked at 72 h of infection, it was nevertheless clearly detectable at early time points 306 
suggesting that UL42 protein is likely to be expressed contemporaneously with degradation 307 
of NEDD4 and NEDD4L (Figure 5C). The route of degradation of each of the UL42 targets 308 
requires further characterisation. MG132 and leupeptin both inhibited degradation of each 309 
protein (Figure 5B), which may correspond to the known effects of MG132 on lysosomal 310 
cathepsins in addition to the proteasome (Wiertz et al., 1996), or effects of leupeptin on 311 
certain proteasomal proteases in addition to lysosomal proteases. 312 
 313 
To test the sensitivity of the interactome for detecting interactions with weakly-expressed 314 
prey, cell surface adhesion molecule Leucine Rich Repeat And Fibronectin Type III Domain 315 
Containing 3 (LRFN3) was examined. This protein was previously quantified by a single 316 
peptide in samples enriched for plasma membrane (PM) proteins only (Nightingale et al., 317 
2018; Weekes et al., 2014). LRFN3 was rapidly downregulated from the PM, accompanied 318 
by upregulation of transcript over the same period, suggesting either degradation or retention 319 
within the infected cell (Figure 5F). Only the ER-resident transmembrane glycoprotein US10 320 
interacted with LRFN3, and this was validated by co-IP (Figures 5G-H). US10 may 321 
downregulate this cell surface molecule in a manner similar to the reported degradation of 322 
HLA-G (Park et al., 2010). 323 
 324 
ORFL147C is a novel viral protein required for viral replication 325 
 326 
It had hitherto been unclear whether any of the 604 HCMV ORFs identified by ribosome 327 
profiling (RP-ORFs) encoded functional polypeptides (Stern-Ginossar et al., 2012). The 328 
abundance of the two RP-ORFs examined in this interactome was in the same range as 329 
canonical HCMV proteins, with ORFL147C present at ~25x lower copy number than the 330 
most abundant tegument protein UL83 and ~275x higher copy number than the membrane 331 
protein US18. ORFS343C was ~3x more abundant than US18 (Figure 1 – Figure 332 
Supplement 1A). ORFL147C had 80 human HCIPs and ORFS343C 23 human HCIPs 333 
(Supplementary File 2). 334 
 335 
The coding sequence of ORFL147C is oriented parallel to the 5’ end of UL56 (Figure 6A), 336 
which is a canonical gene encoding a subunit of terminase. ORFL147C is expressed with Tp4 337 
kinetics (Figure 6B). Enrichment analysis of ORFL147C HCIPs suggested functions in RNA 338 
binding, mRNA splicing or transcription (Figure 6C-D). We validated the interaction of 339 
ORFL147C with Muscleblind Like Splicing Regulator 1 (MBNL1) and CUG Triplet Repeat 340 
RNA-Binding Protein 1 (CELF1), two proteins with roles in mRNA splicing and RNA 341 
binding (Figure 6E). 342 
 343 
To test whether ORFL147C plays an important role in viral replication, possibly via a 344 
splicing or transcriptional mechanism, an HCMV recombinant was generated in which the 345 
three most N-terminal methionine residues in ORF147C were mutated without modifying the 346 
coding sequence of UL56. The growth of ORFL147C virus was significantly impaired, 347 
suggesting that ORFL147C plays an important functional role during viral infection (Figure 348 
6F-G). The large HCIP network for ORFL147C suggests that various mechanisms 349 
underlying this observation need to be examined; it is as yet unclear whether splicing or 350 
transcriptional effects are important. 351 
 352 
DISCUSSION 353 
In the present study, we report the largest host-pathogen interactome to date and the first 354 
comprehensive interactome map for a DNA virus in infected cells. This has suggested 355 
functions and domain associations for multiple uncharacterized or partly characterized viral 356 
proteins, in addition to providing evidence that the non-canonical HCMV proteins 357 
ORFL147C and ORFS343C may be functional. The searchable database provided details 358 
virus-virus and virus-host interactions for 162/171 HCMV proteins, and will be of significant 359 
value in future studies of HCMV and other herpesviruses. 360 
Different herpesviruses exhibit certain common functions (Mocarski Jr, 2007). A previous 361 
study identified 564 human HCIPs of Kaposi’s sarcoma-associated herpesvirus (KSHV) 362 
(Davis et al., 2015). Comparison of HCMV and KSHV interactomes revealed that baits from 363 
both viruses interacted with 176 identical human prey, including RNA Pol II, CCR4-NOT 364 
and CTLH components, and elements of the ubiquitin conjugation pathway. It will be 365 
important in future studies to determine which of these common functions are mediated by 366 
orthologous proteins, and which by distinct viral mechanisms. Conversely, certain HCMV 367 
prey did not interact with KSHV baits, including mRNA splicing machinery components 368 
(Figure 7). Comparisons with interactomes from additional herpesviruses when generated 369 
will help to delineate functions exhibited by all herpesvirus genera, and those more specific 370 
to individual viruses or viral subfamilies. 371 
The combination of interactome data generated in the present study with our previous screens 372 
of protein degradation during early HCMV infection (Nightingale et al., 2018) identified the 373 
viral UL42 protein as a hub of degradation for multiple ubiquitin E3 ligases, and predicted 374 
novel interactions between viral baits and 29 other degraded cellular prey. More broadly, we 375 
discovered that HCMV devotes multiple proteins to interactions with the ubiquitin 376 
conjugation pathway, with 18 viral proteins interacting with two or more E3 ligases (defined 377 
in (Medvar et al., 2016) and 51 viral proteins interacting with one or more E3 ligase. Details 378 
of such interactions can potentially identify viral mechanisms of cellular protein degradation. 379 
For example, UL25 interacted with the adaptor protein WD Repeat Domain 26 (WDR26), 380 
which can recruit substrates to the Cullin-4 RING ubiquitin ligase family (Higa et al., 2006). 381 
UL25 interacted with UL26, which itself interacted with 9 out of 10 members of the CTLH 382 
complex, a homologue of the yeast glucose-induced degradation-deficient machinery. This 383 
complex has inherent E3 ligase activity, however so far substrates have not been well defined 384 
(Francis et al., 2013; Salemi et al., 2017). Finally, UL26 also interacted with other ligases and 385 
scaffolds, such as Cullin 3 and SMAD Specific E3 Ubiquitin Protein Ligase 2 (SMURF2). 386 
Future work is likely to identify whether UL25 or UL26 prey are degraded, and which of 387 
these cellular pathways are employed. 388 
The present study also highlights other viral ‘hubs’ of protein degradation. For example, 389 
HCMV UL20 was previously found to be rapidly degraded, with the suggestion it may target 390 
unidentified cellular proteins to lysosomes (Jelcic et al., 2011). Here, we identify candidate 391 
cellular targets. For example, UL20 interacted with Interleukin 6 Signal Transducer (IL6ST), 392 
the neonatal Fc receptor (FCGRT), Ephrin A2 (EPHA2), and Interferon Gamma Receptor 1 393 
(IFNGR1), all of which we have previously shown are rescued from degradation by 394 
application of the lysosomal protease inhibitor Leupeptin. Interestingly, all four proteins were 395 
also rescued by targeted deletion of members of the viral US12-US21 family of paralogous 396 
genes (Fielding et al., 2017). This suggests that there may be cooperativity between the 397 
US12-US21 proteins and UL20, possibly with UL20 acting in a final common pathway.  398 
All systematic interactomes of this type include false discoveries and fail to detect certain 399 
genuine interactions. However, a particular advantage of considering multiple interactions 400 
simultaneously in comparison to isolated IP-MS experiments is a much lower false discovery 401 
rate (estimated ~5%), as non-specific interacting proteins can be excluded because they are 402 
commonly identified in multiple different IPs (Sowa et al., 2009). The present study also 403 
identified a subset of VHCIPs by employing two distinct filtering strategies, which will assist 404 
future investigations based on our data. It is difficult to estimate a true false negative rate, 405 
since there is no gold standard for assessing true interactions, and the published literature also 406 
suffers from false discoveries. One factor that may contribute to missed identifications is the 407 
abundance of the prey protein. The present study clearly has the ability to identify some 408 
interacting proteins present at low cellular abundance, exemplified by identification of the 409 
interaction between US10 and LRFN3. LRFN3 was below the limit of detection in two 410 
unbiased quantitative proteomic studies of >8,000 proteins from whole cell lysates of HFFFs 411 
(Supplementary File 1C). However, 36% of previously described interactions that were not 412 
identified in the present study were also unquantified in whole cell lysates (Supplementary 413 
File 3), suggesting that protein abundance may play a significant role in interaction 414 
discovery. Furthermore, degradation of human prey proteins during HCMV infection may 415 
also impact the limit of detection by MS. For example, although RL1 interacted with the 416 
Cullin 4 scaffold and two associated proteins, no other high confidence RL1 prey were 417 
identified. It will therefore be important to repeat this interactome in the presence of 418 
lysosomal and proteasomal inhibition to identify such targets. Additionally, for future 419 
investigations of our data, validation of interactions in which the prey protein has low cellular 420 
abundance as indicated in Supplementary File 2B may be best performed by overexpression 421 
studies as opposed to attempts to co-IP the endogenous protein. 422 
Overexpression of each bait throughout the course of infection may have led to temporal 423 
dysregulation of the expression of other viral proteins, and may have facilitated interactions 424 
that would usually commence earlier or later than 60 h of infection. However, as 153/153 425 
quantified viral ORFs were expressed at 60 h (Weekes et al., 2014), the observed interactions 426 
should occur at this phase of infection even if either bait or prey protein or both were not 427 
maximally expressed. Stable overexpression of the viral bait might have enabled false 428 
positive interactions. However, certain proteins endogenously expressed by HCMV are 429 
already under the control of strong promoters (Mocarski et al., 2013). Indeed, the abundance 430 
of certain stably expressed proteins may actually have been lower than the abundance of the 431 
same proteins expressed during HCMV infection. From our IBAQ analysis of host and viral 432 
protein abundance averaged across 24, 48 and 72 h of HCMV infection, the most abundant 433 
viral protein (UL83) was expressed ~2.4-fold more than the most abundant host protein 434 
(Galectin-1), and the least abundant viral protein ~62-fold more than the least abundant host 435 
protein (Supplementary File 1A,  Supplementary File 1C), suggesting that the range of 436 
expression of viral proteins was already shifted towards the higher end of host protein 437 
expression. Prior human interactome studies have found no correlation between bait protein 438 
expression and the number of HCIPs (Sowa et al., 2009). Alternative strategies to conduct an 439 
interactome study would also suffer from potential confounding issues. For example, 440 
introduction of a tag into the viral genome prior to or after each coding sequence may 441 
facilitate expression of the bait at the same time and level as during infection with 442 
unmodified virus. However, due to the occurrence of polycistronic transcription of viral 443 
genes and overlapping viral ORFs (Stern-Ginossar et al., 2012), introduction of a tag may 444 
disrupt expression of neighbouring genes. 445 
A large number of noncanonical ORFs were identified by ribosome profiling as potentially 446 
being translated (RP-ORFs,(Stern-Ginossar et al., 2012), and 13 novel ORFs from a six-447 
frame translation of the HCMV genome sequence were recognised as being represented in 448 
MS data (6FT-ORFs,(Nightingale et al., 2018). However, these studies produced no evidence 449 
that any of these ORFs encode functional proteins. The present study identified three RP-450 
ORFs and 2/13 6FT-ORFs as interactors of canonical HCMV proteins, and identified seven 451 
additional interacting 6FT-ORFs for the first time. There is thus a case for functional 452 
investigations of a modest number of additional ORFs, and initial prediction of these 453 
functions can be achieved by interaction analysis. For example, although the precise function 454 
of ORFL147C remains to be determined, we validated interactions with proteins involved in 455 
mRNA splicing including MBNL1 and CELF1. Other interactors with roles in RNA binding, 456 
such as Ribonucleotide PTB-binding 1 (RAVER1) modulates alternative splicing events. 457 
Spliced transcripts have long been recognized from HCMV at all times post infection 458 
(Rawlinson et al., 1993), and more recently up to 100 splice junctions have been identified 459 
(Balazs et al., 2017; Gatherer et al., 2011; Stern-Ginossar et al., 2012). 460 
Only three drugs are currently available to treat HCMV infection, and all suffer from 461 
significant side effects and the threat of the development of resistance. In the context of the 462 
increasing frequency of transplantation, innovative therapeutic strategies are required. The 463 
identification of key interactions in virus-virus or virus-host protein complexes may be 464 
important in this regard, since small molecule inhibitors may be able to disrupt these 465 
interactions or restore endogenous antiviral restriction by preventing host protein degradation 466 
(Cen et al., 2010; Nathans et al., 2008; Pery et al., 2015). To identify bait-prey pairs 467 
amenable to straightforward therapeutic interruption, it is desirable to identify factors targeted 468 
by a single viral protein, for example members of the CNOT complex by UL72. In addition 469 
to the interaction between UL72 and individual CNOT members, CNOT effector function 470 
could also be an antiviral target, for example employing inhibitors of the CNOT7 471 
deadenylase (Maryati et al., 2014). Ideally, similar interactions involving several distinct 472 
pathways might be targeted simultaneously to inhibit viral replication in a way that is 473 
refractory to resistance. As an additional strategy, the recent identification of putative ligands 474 
for the viral GPCRs may facilitate approaches to targeting cytotoxins exclusively to infected 475 
cells (Krishna et al., 2017). These considerations illustrate the potential of the interactome 476 
data in the present study for identifying biologically important protein-protein interactions 477 
and developing antiviral therapies based on their disruption. 478 
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Key Resources Table 775 
 776 
Reagent 
type 
Designation Source or reference Identifiers Additional 
information 
strain, strain 
background 
(HCMV) 
HCMV Merlin Stanton et al, 2010 RCMV1111  
strain, strain 
background 
(HCMV) 
HCMV Merlin UL36-
GFP deltaORFL147C 
This paper RCMV2697  Available from Dr 
Michael Weekes’ 
lab, University of 
Cambridge 
strain, strain 
background 
(HCMV) 
HCMV Merlin UL36-
GFP 
Nightingale et al, 
2018 
RCMV2582   
strain, strain 
background 
(Escherichia 
coli) 
E. coli. (α-Select 
Silver Competent 
Cells) 
Bioline Cat# BIO-85026  
cell line 
(Homo-
sapiens) 
HFFF immortalized 
with human 
telomerase (HFFF-
TERT) 
McSharry et al 2001   
cell line 
(Homo-
sapiens) 
Human Embryonic 
Kidney 293T cells 
Menzies et al 2018 ATCC Cat# CRL-
3216, 
RRID:CVCL_0063  
 
antibody Anti-V5 Agarose 
Affinity Gel 
Sigma-Aldrich Cat#A7345; 
RRID:AB_10062721 
(30µl/mL) 
antibody Mouse monoclonal 
anti-GAPDH  
R&D Systems Cat#MAB5718; 
RRID:AB_10892505 
(1:10.000) 
antibody Rabbit polyclonal 
anti-Calnexin 
LifeSpan 
Biosciences 
Cat#LS-B6881; 
RRID:AB_11186721 
(1:10.000) 
antibody Rabbit monoclonal 
anti-HA (C29F4) 
Cell Signaling 
Technologies 
Cat#3724S; 
RRID:AB_1549585 
(1:1000) 
antibody Mouse monoclonal 
anti-V5 
Thermo Cat# R960-25; 
RRID:AB_2556564 
(1:5000) 
antibody Rabbit polyclonal 
anti-CNOT2  
Novus Biologicals Cat# NBP2-56034; 
RRID:AB_2801658 
(1:1000) 
antibody Rabbit monoclonal 
anti-CNOT7 
Abcam Cat# ab195587; 
RRID:AB_2801659 
(1:1000) 
antibody Mouse monoclonal 
anti-NEDD4 
R&D Systems Cat# MAB6218; 
RRID:AB_10920762 
(1:1000) 
antibody IRDye 680RD goat 
anti-mouse IgG 
LI-COR Cat#925-68070, 
RRID:AB_2651128 
(1:10.000) 
antibody IRDye 800CW goat 
anti-rabbit IgG 
LI-COR Cat#925-32211, 
RRID:AB_2651127 
(1:10.000) 
antibody IRDye 680RD goat 
anti-rabbit IgG 
LI-COR Cat#926-68071; 
RRID:AB_10956166 
(1:10.000) 
antibody IRDye 800CW goat 
anti-mouse IgG 
LI-COR Cat#926-32210; 
RRID:AB_621842 
(1:10.000) 
antibody Human TruStain FcX BioLegend Cat#422302; 
RRID:AB_2818986 
1:20 
recombinant 
DNA reagent 
pHAGE-pSFFV Nightingale et al, 
2018 
  
recombinant 
DNA reagent 
pDONR223 Nightingale et al, 
2018 
  
recombinant pDONR221-MBLN1  Harvard PlasmID Cat# HsCD00079833  
DNA reagent 
recombinant 
DNA reagent 
pDONR221-CUGBP1  Harvard PlasmID  Cat# HsCD00039403  
recombinant 
DNA reagent 
pOTB7-CUL4A Harvard PlasmID  Cat# HsCD00325140  
recombinant 
DNA reagent 
pCMV-SPORT6-
NEDD4L  
Harvard PlasmID  Cat# HsCD00337956  
recombinant 
DNA reagent 
pENTR223-NCK1  Harvard PlasmID Cat# HsCD00370605  
recombinant 
DNA reagent 
pDONR223-CNOT2  Harvard PlasmID  Cat# HsCD00080019  
recombinant 
DNA reagent 
pHAGE-CNOT7  Harvard PlasmID Cat# HsCD00453329  
recombinant 
DNA reagent 
PHAGE-P-CMVt-N-
HA Nedd4 wt  
Addgene  Cat# 24124  
recombinant 
DNA reagent 
pDONR221-LRFN3  Harvard PlasmID  Cat# HsCD00041564  
sequence-
based 
reagent 
M13-F GENEWIZ PCR primers GTAAAACGAC
GGCCAG 
sequence-
based 
reagent 
M13-R  GENEWIZ PCR primers CAGGAAACAG
CTATGAC 
sequence-
based 
reagent 
pHAGE-pSFFV-Seq This paper PCR primers CGCGCCAGTCC
TCCGATTG 
sequence-
based 
reagent 
GAW-CMVp-F This paper PCR primers GGGACAAGTTT
GTACAAAAAA
GCAGCTGAAG
ACACCGGGACC
GATC 
sequence-
based 
reagent 
attB2-V5-R This paper PCR primers GGGGACCACTT
TGTACAAGAAA
GCTGGGTTTAC
GTAGAATCAAG
ACCTAGGAGC 
peptide, 
recombinant 
protein 
V5 Epitope Tag Alpha Diagnostic 
International 
Cat# SP-59199-5  
peptide, 
recombinant 
protein 
Trypsin Promega Cat# V5111  
commercial 
assay or kit 
BCA Protein Assay 
Kit 
Thermo Fisher Cat# 23227  
commercial 
assay or kit 
Micro BCA Protein 
Assay Kit 
Thermo Fisher Cat# 23235  
commercial 
assay or kit 
RNeasy Mini Kit Qiagen Cat#74104  
commercial 
assay or kit 
Empore™ SPE Disks Supelco Cat# 66883-U  
commercial 
assay or kit 
GoScript Reverse 
Transcriptase kit 
Promega  Cat#A5001  
commercial 
assay or kit 
Power SYBR® Green 
PCR Master Mix 
Thermo Fisher Cat#4367659  
commercial 
assay or kit 
Gateway BP Clonase 
II Enzyme Mix 
Invitrogen Cat# 56481  
commercial 
assay or kit 
Gateway LR Clonase 
Enzyme Mix 
Invitrogen Cat# 56484  
chemical Dexamethasone Sigma-Aldrich Cat#D4902  
compound, 
drug 
chemical 
compound, 
drug 
DL-Dithiothreitol Sigma-Aldrich Cat# 43815-1G  
software, 
algorithm 
“MassPike”, a 
Sequest-based 
software pipeline for 
quantitative 
proteomics. 
Professor Steven 
Gygi’s lab, Harvard 
Medical School, 
Boston, USA. 
  
software, 
algorithm 
SEQUEST Eng et al 1994   
software, 
algorithm 
DAVID software https://david.ncifcrf.
gov/ 
DAVID, 
RRID:SCR_001881 
 
software, 
algorithm 
Reactome software https://reactome.org/ Reactome, 
RRID:SCR_003485 
 
software, 
algorithm 
Image Studio Lite LI-COR Ver. 5.2; Image 
Studio Lite, 
RRID:SCR_013715 
 
software, 
algorithm 
Cytoscape The Cytoscape 
Consortium 
Ver 3.7.1; Cytoscape, 
RRID:SCR_003032 
 
software, 
algorithm 
DNASTAR Lasergene 
- SeqBuilder 
DNASTAR, Inc. Ver. 12; DNASTAR: 
Lasergene Core 
Suite, 
RRID:SCR_000291 
 
software, 
algorithm 
FlowJo FlowJo Ver. 10; FlowJo, 
RRID:SCR_008520 
 
software, 
algorithm 
CompPass  Sowa et al 2009   
software, 
algorithm 
CompPass Plus  Huttlin et al 2015   
other Orbitrap Fusion Mass 
Spectrometer 
ThermoFisher 
Scientific 
Cat# IQLAAEGAAP 
FADBMBCX 
Instrument 
other Orbitrap Fusion 
Lumos Mass 
Spectrometer 
ThermoFisher 
Scientific 
Cat# IQLAAEGAAP 
FADBMBHQ 
Instrument 
other Raw Mass 
Spectrometry Data 
Files 
This paper  ProteomeXchange 
Consortium via the 
PRIDE partner 
repository with 
dataset identifier 
PXD014845. 
Raw data 
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 779 
Cells and cell culture 780 
Human fetal foreskin fibroblast cells immortalised with human telomerase (HFFF-TERTs, 781 
male) and HEK293T cells (female) were grown in Dulbecco’s modified Eagle’s medium 782 
(DMEM) supplemented with foetal bovine serum (FBS: 10% v/v), and 100 IU/ml penicillin / 783 
0.1 mg/ml streptomycin (DMEM/FBS/PS) at 37°C in 5% v/v CO2. HFFF-TERTs have been 784 
tested at regular intervals since isolation to confirm that human leukocyte antigen (HLA) and 785 
MHC Class I Polypeptide-Related Sequence A (MICA) genotypes, cell morphology and 786 
antibiotic resistance are unchanged. In addition, HCMV strain Merlin grows only in human 787 
fibroblast cells (dermal or foreskin in origin), further reducing the possibility that they have 788 
been contaminated with another cell type. HEK293T cells were obtained as a gift from 789 
Professor Paul Lehner and had been authenticated by Short Tandem Repeat profiling 790 
(Menzies et al., 2018). All cells were confirmed to be mycoplasma-negative (Lonza 791 
MycoAlert).  792 
 793 
Viruses 794 
The genome sequence of HCMV strain Merlin is designated the reference for HCMV by the 795 
National Center for Biotechnology Information, and was originally sequenced after 3 796 
passages in human fibroblast cells (Dolan et al., 2004). A recombinant version (RCMV1111) 797 
of this strain was derived by transfection of a sequenced BAC clone (Stanton et al., 2010). 798 
RCMV1111 contains point mutations in two genes (RL13 and UL128) that enhance 799 
replication in fibroblasts (Stanton et al., 2010). 800 
HCMV expressing rGFP from a P2A self-cleaving peptide at the 3’-end of the UL36 coding 801 
region (RCMV2582) was generated by recombineering the strain Merlin BAC as described 802 
previously (Stanton et al., 2010). An ORFL147C mutant (RCMV2697) was generated by 803 
recombineering RCMV2582. Substitutions were introduced into three in-frame ATG codons 804 
at or near the 5’-end of ORFL147C, in such a way that the coding potential of UL56, with 805 
which ORFL147C overlaps extensively in another reading frame, was unaffected. Whole-806 
genome consensus sequences of passage 2 of all recombinant viruses were derived using the 807 
Illumina platform as described previously (Fielding et al., 2014) 808 
Viral stocks were prepared from HFFF-TERTs as described previously (Stanton et al., 2007). 809 
When complete cytopathic effect was observed, cell culture supernatants were centrifuged to 810 
remove cell debris and then centrifuged at 22,000 × g for 2 h to pellet cell-free virus. The 811 
virus was resuspended in fresh DMEM, and residual debris was removed by centrifugation at 812 
16,000 x g for 1 min. In total, 17 stocks of RCMV1111 were required for this project. To 813 
ensure identical infection conditions between every batch of viral infections, each stock was 814 
divided into 25 aliquots. For each batch of infections, one aliquot of each stock was thawed 815 
then all 17 aliquots combined and mixed prior to infection. 816 
 817 
Plasmid construction 818 
For the majority of HCMV genes, a library of recombinant adenovirus vectors (RAds) was 819 
used to generate lentiviral constructs. Each template expresses a C-terminally V5-tagged gene 820 
under the control of the HCMV major immediate early promoter, with a 6 bp linker region 821 
between the end of the gene and the tag. Of 169 genes cloned into RAds, expression was 822 
confirmed for 160 by a combination of IB (152 genes) and immunofluorescence (155 genes). 823 
The codon usage of US14, US17 and UL74 was optimized for expression ( Supplementary 824 
File 1D) (Seirafian, 2012). To amplify genes from the RAds, primers were designed to 825 
recognise the 3’ end of the HCMV promoter (forward ‘GAW-CMVp-F’) and the 3’ end of 826 
the V5 tag (reverse ‘attB2-V5-R’). Both primers had flanking Gateway attB sequences 827 
(Supplementary File 1E, Key Resources Table). 828 
For HCMV genes amplified from the RCMV1111 BAC, primers were designed to recognize 829 
the 3’ end and the 5’ end of each gene (Supplementary File 1E). In addition to the gene-830 
specific sequence, the reverse primer also contained a 6 bp linker region, followed by the 831 
coding sequence for the V5 tag and a stop codon. Both primers had flanking Gateway attB 832 
sequences.  833 
A subset of HCMV genes was synthesized as double-stranded DNA fragments (gBlocks®, 834 
Integrated DNA Technologies, detailed in the Supplementary File 1E ‘Template’ column). 835 
Each fragment comprised the viral gene (without a stop codon), succeeded by a 6 bp linker 836 
region, the coding sequence for the V5 tag then the stop codon. The fragments had flanking 837 
Gateway attB sequences. The sequences of all primers and HCMV genes used in this study 838 
are shown in Supplementary File 1D-E and the Key Resources Table. 839 
Two control vectors were additionally employed. ‘GAW Control’ contains a short DNA 840 
sequence (produced by a random DNA sequence generator) flanked by Gateway attB 841 
sequences. Complementary oligonucleotides (Supplementary File 1E) were annealed to 842 
generate a double-stranded DNA fragment, which was then inserted into pDONR223 by 843 
gateway recombination. A second control vector coding for GFP was cloned from the 844 
adenoviral template library as described above. Neither the ‘GAW Control’ nor GFP were 845 
tagged with V5. 846 
For HA-tagged human genes (Figures 3-6), primers were designed to recognise the 3’ end 847 
and 5’ end of each gene (Supplementary File 1F). In addition to the gene-specific sequence, 848 
the reverse primer also contained a 6 bp linker region, followed by the coding sequence for 849 
an HA tag and a stop codon. Both primers had flanking Gateway attB sequences. 850 
PCR employed PfuUltra II Fusion HS DNA polymerase (Agilent). Constructs were 851 
subsequently cloned into the pDONR223 entry vector, then into the lentiviral destination 852 
vector pHAGE-pSFFV using the Gateway system (Thermo Scientific). pHAGE-pSFFV has a 853 
spleen focus-forming virus (SFFV) promoter replacing the HCMV promoter in pHAGE-854 
pCMV to prevent promoter inactivation during HCMV infection (Nightingale et al., 2018). 855 
For UL48, which is 6.7 kbp long, it was not possible to express the whole construct via 856 
lentiviral transduction alone, probably due to inefficient transduction. UL48 contains a 857 
predicted -helix from residues 540-1500, but no predicted secondary structure between 858 
residues 1501-1509. The gene was therefore divided into two segments, one of 4.5 kbp (1-859 
1504 aa) terminating in a stop codon, and one of 2.2 kbp (1505-2241 aa), with an additional 860 
start codon. Both segments were stably expressed in different cell lines, and HCMV-infected 861 
cellular lysates were combined prior to IP. Full sequencing of all genes was conducted in the 862 
pDONR223 vector using standard primers and additional internal primers as required (Key 863 
Resources Table). All pHAGE-pSFFV vectors underwent sequencing of the first ~700 864 
nucleotides from the 3’ end of the SFFV promoter to verify that the viral construct had 865 
recombined correctly. 866 
 867 
Stable cell line production 868 
Lentiviral particles were generated through transfection of HEK293T cells with the lentiviral 869 
transfer vector and four helper plasmids (VSVG, TAT1B, MGPM2, CMV-Rev1B), using 870 
TransIT-293 transfection reagent (Mirus) according to the manufacturer's recommendations 871 
(Nightingale et al., 2018). Viral supernatant was harvested 48 h post-transfection and cell 872 
debris was removed with a 0.22 μm filter. To facilitate stable, constitutive expression of the 873 
viral transgene, target cells were transduced for 48 h and then subjected to antibiotic selection 874 
for two weeks. 875 
 876 
Immunoblotting to confirm viral bait expression 877 
Lysates for each HFFF-TERT cell line expressing a viral bait were tested for transgene 878 
expression by IB for the V5 tag. Cells were lysed with RIPA buffer (Cell Signaling) 879 
containing Complete Protease Inhibitor Cocktail (Roche) and clarified by centrifugation at 880 
16,000 x g for 10 min. Protein concentration was measured by BCA (Pierce) using the 881 
manufacturer’s protocol. Lysates were reduced with 6X Protein Loading Dye (375 mM Tris-882 
HCl pH 6.8, 12% w/v sodium dodecyl sulphate (SDS), 30% v/v glycerol, 0.6 M dithiothreitol 883 
(DTT), 0.06% w/v bromophenol blue) for 5 min at 95°C. 20 g of protein for each sample 884 
was separated by polyacrylamide gel electrophoresis (PAGE) using 4-15% TGX Precast 885 
Protein Gels (Bio-rad), then transferred to polyvinylidene difluoride (PVDF) membranes 886 
using Trans-Blot Systems (Bio-rad). The following primary antibodies were used: anti-V5 887 
(MA5-15253, Thermo) and anti-Calnexin (CANX, LS-B6881, LifeSpan BioSciences). 888 
Secondary antibodies were IRDye 680RD goat anti-rabbit (926-68071, LI-COR) and IRDye 889 
800CW goat anti-mouse (926-32210, LI-COR). Fluorescent signals were detected using a LI-890 
COR Odyssey, and images were processed using Image Studio Lite (LI-COR). 891 
Where viral baits could not be detected by IB, IP-MS was used with uninfected cellular 892 
lysates as described below in ‘IP and protein digestion for proteomic experiments’. Where a 893 
bait could not be detected by IP-MS, RT-qPCR was used as described below. 894 
 895 
 896 
RT-qPCR to confirm viral bait expression 897 
Total RNA from a subset of HFFF-TERT lines expressing viral transgenes was extracted 898 
using an RNeasy Mini Kit (Qiagen). cDNA was synthesized using GoScript Reverse 899 
Transcriptase (Promega), followed by RT-qPCR using Fast SYBR Green Master Mix 900 
(Applied Biosystems) and 7500 Fast & 7500 Real-Time PCR Systems (Applied Biosystems). 901 
Primers targeting HCMV genes or GAPDH (as an internal control) are shown in  902 
Supplementary File 1E. The PCR program started with activation at 95°C for 2 min, 903 
followed by 40 cycles of denaturation at 95°C for 5 s and annealing/extension at 60°C for 30 904 
s. The amplification products were then separated by agarose gel electrophoresis, purified 905 
(QIAquick Gel Extraction, Qiagen) and sequenced to confirm viral bait expression. For 906 
UL146 and UL148D, this procedure failed to generate sequenceable amplicons, and UL136 907 
failed to generate any PCR product despite the use of primers that recognized both a short 908 
and full-sized amplicon (Supplementary File 1E). For UL146 and UL148D, whole gene 909 
amplicons (189-363 bp) were generated by PCR with PfuUltra II Fusion HS DNA 910 
Polymerase (Agilent), according to the manufacturer’s recommendations. Sequencing of the 911 
amplified product confirmed expression of the correct gene in each case. 912 
 913 
Virus infections for IP-MS proteomic experiments 914 
Each batch of viral infections included eight cell lines stably expressing different viral baits 915 
in duplicate. For each cell line, 6 x 10
6
 cells were plated in DMEM/FBS/PS in each of two 916 
150 cm
2
 dishes. After 24 h, the medium was changed to DMEM lacking FBS but with 4 917 
μg/ml dexamethasone, as this approach has been shown to improve infection efficiency 918 
(Tanaka et al., 1984). After 24 h, the medium was changed to DMEM containing the requisite 919 
volume of HCMV strain Merlin stock to achieve MOI 2. Cells were gently rocked for 2 h, 920 
and then the medium was changed to DMEM/FBS/PS and cells were incubated for a further 921 
58 h. 922 
 923 
IP and protein digestion for IP-MS proteomic experiments 924 
Cells were harvested in one of two lysis buffers in order to best solubilise each bait protein 925 
and preserve protein-protein interactions. For soluble and single-pass transmembrane (TM) 926 
baits, cells were lysed in (50 mM Tris-HCl pH 7.5, 300 mM NaCl, 0.5% v/v NP40, 1 mM 927 
DTT and Roche protease inhibitor cocktail). Baits with two or more TM domains were 928 
solubilized in 1% w/v digitonin (Merck Millipore) in TBS (Sigma) and Roche protease 929 
inhibitor cocktail. Transmembrane predictions were derived from Uniprot (www.uniprot.org) 930 
for canonical HCMV proteins, and generated using TMHMM for the two novel proteins 931 
(Krogh et al., 2001). Samples were tumbled for 15 min at 4°C and then centrifuged at 16,100 932 
g for 15 min at 4°C. Lysates were then clarified by filtration through a 0.7 µm filter and 933 
incubated for 3 h with immobilised mouse monoclonal anti-V5 agarose resin (Sigma). 934 
Duplicate samples were combined for resin washes. Samples lysed in NP40-containing buffer 935 
were washed seven times with lysis buffer, followed by seven PBS pH 7.4 washes. Samples 936 
lysed in digitonin-containing buffer were washed once with lysis buffer, twice with 0.2% 937 
(w/v) digitonin in TBS and then once with TBS. Subsequently, proteins bound to the anti-V5 938 
resin were eluted twice by adding 200 µl of 250 μg/ml V5 peptide (Alpha Diagnostic 939 
International) in PBS at 37°C for 30 min with agitation. Finally, proteins were precipitated 940 
with 20% TCA, washed once with 10% TCA, washed three times with cold acetone and dried 941 
to completion using a centrifugal evaporator. Samples were resuspended in digestion buffer 942 
(50 mM Tris-HCl pH 8.5, 10% acetonitrile (AcN), 1mM DTT, 10 ug/ml Trypsin) and 943 
incubated overnight at 37°C with agitation. The reaction was quenched with 50% formic acid 944 
(FA), subjected to C18 solid-phase extraction, and vacuum-centrifuged to complete dryness. 945 
Samples were reconstituted in 4% acetonitrile / 5% formic acid and divided into technical 946 
duplicates prior to LC-MS/MS on an Orbitrap Lumos. To minimise variability in sample 947 
preparation, all samples were lysed with aliquots from the same batch of lysis buffer. 948 
Similarly, several batches of the anti-V5 agarose resin used for immunoprecipitation were 949 
pooled and this pool was used for all samples. In addition, all V5 peptide used for protein 950 
elution was derived from the same manufacturer’s batch, and all protein digests were 951 
performed with aliquots from the same stock of digestion buffer. 952 
 953 
LC-MS/MS for IP-MS experiments 954 
Peptides for each sample were analysed in technical duplicate, with the run order reversed 955 
from one batch of replicate analyses to the next to ensure that any carry-over was different in 956 
each case. Two washes were used between each sample to further minimise carry-over (i.e. 957 
Run 1: Sample A, wash, wash, Sample B, wash, wash, Sample C…; Run 2: …Sample C, 958 
wash, wash, Sample B, wash, wash, Sample A). Individual batches included 16-22 samples. 959 
To ensure consistent performance by the mass spectrometer between batches, an identical 960 
aliquot of a control IP of uninfected cells stably expressing the viral UL123 gene with a C-961 
terminal V5 tag was included with each batch. The number of peptides in total, from the bait, 962 
and from known UL123 prey were very similar between batches. 963 
The major reason for pooling the biological replicates and analyzing samples in technical 964 
duplicate was to solve certain technical issues. Specifically, due to the potential for carry-965 
over of peptides between adjacent injections of different IP samples, it was necessary to use 966 
consistency of detection of prey as a measure of confidence in bait-prey interaction. To 967 
electronically filter out carry-over contaminants, an entropy score (described below in ‘Data 968 
analysis’) compared the number of peptide-spectrum matches (PSM) between technical 969 
replicate injections and eliminated prey that were not detected consistently. In addition, this 970 
form of replicate analysis also enabled false positive interactions to be minimised since the 971 
same random incorrect interaction was unlikely to appear twice in two different runs. It was 972 
therefore important that replicate injection material was as similar as possible to ensure that 973 
this filter was efficacious. These issues are well understood and examined in (Huttlin et al., 974 
2015); the CompPass algorithm (described below) was developed based on this specific 975 
protocol. 976 
To directly examine biological variability, six of the IP-MS experiments were re-run, with 977 
independent analysis of each replicate. There was very good correlation between the number 978 
of PSM from each identified prey protein both between biological as well as between 979 
technical replicates (Figure 1 – Figure Supplement 1C-D). 980 
Mass spectrometry data were acquired using an Orbitrap Fusion Lumos. An Ultimate 3000 981 
RSLC nano UHPLC equipped with a 300 µm ID x 5 mm Acclaim PepMap µ-Precolumn 982 
(Thermo Fisher Scientific) and a 75 µm ID x 75 cm 2 µm particle Acclaim PepMap RSLC 983 
analytical column was used. 984 
Loading solvent was  0.1% v/v FA, and the analytical solvents were (A) 0.1% v/v FA and (B) 985 
80% v/v MeCN + 0.1% v/v FA. All separations were carried out at 55°C. Samples were 986 
loaded at 5 µl/min for 5 min in loading solvent before beginning the analytical gradient. The 987 
following gradient was used: 3-7% B over 3 min then 7-37% B over 54 min followed by a 4 988 
min wash in 95% B and equilibration in 3% B for 15 min. The following settings were used: 989 
MS1, 350-1500 Thompsons (Th), 120,000 resolution, 2x10
5
 automatic gain control (AGC) 990 
target, 50 ms maximum injection time. MS2, quadrupole isolation at an isolation width of 991 
m/z 0.7, higher-energy collisional dissociation (HCD) fragmentation (normalised collision 992 
energy (NCE) 34) with fragment ions scanning in the ion trap from m/z 120, 1x10
4
 AGC 993 
target, 250 ms maximum injection time, with ions accumulated for all parallelisable times. 994 
The method excluded undetermined and very high charge states (≥25+). Dynamic exclusion 995 
was set to +/- 10 ppm for 25 s. MS2 fragmentation was trigged on precursors 5x10
3
 counts 996 
and above. Two 45 min washes were included between every affinity purification-mass 997 
spectrometry (AP-MS) analysis, to minimise carry-over between samples. 1 µl transport 998 
solution (0.1% v/v TFA) was injected, over the following gradient: 3-40% B over 29 min 999 
followed by a 3 min wash at 95% B and equilibration at 3% B for 10 min. 1000 
 1001 
Confirmation of ORFL147C deletion in ΔORFL147C recombinant virus 1002 
 1003 
For Figure 6G, HFFF-TERT cells were infected as otherwise described in ‘Virus infections 1004 
for IP-MS proteomic experiments’ with the following modifications: 1.5 x 105 cells seeded 1005 
per well of a 12-well plate for a total of 48 h infection. A total infection duration of 48 h was 1006 
selected as ORFL147C expression peaks at this time (Figure 6B). 1007 
As described in (Nightingale et al., 2018) and briefly recapitulated here, cells were washed 1008 
with PBS, lysed with 6M Guanidine/50 mM HEPES pH 8.5, scraped, vortexed extensively 1009 
then sonicated then debris removed by centrifugation. Proteins were reduced using DTT then 1010 
cysteines alkylated with iodoacetamide, which was quenched with DTT. Samples were 1011 
diluted with HEPES pH 8.5 to 1.5 M Guanidine followed by digestion at room temperature 1012 
for 3 h with LysC protease at a 1:100 protease-to-protein ratio. Samples were further diluted 1013 
with 200 mM HEPES pH 8.5 to 0.5 M Guanidine. Trypsin was then added at a 1:100 1014 
protease-to-protein ratio followed by overnight incubation at 37°C. The reaction was 1015 
quenched with 5% formic acid, then centrifuged at 21,000 g for 10 min to remove undigested 1016 
protein. Peptides were subjected to C18 solid-phase extraction (SPE, Sep-Pak, Waters) and 1017 
vacuum-centrifuged to near-dryness. 1018 
Desalted peptides were dissolved in 200 mM HEPES pH 8.5 and peptide concentration was 1019 
measured by microBCA, 15 g of peptide was labeled with TMT reagent (mock - 126; wild-1020 
type – 127N; ORFL147C – 128N). After 1 h, the reaction was quenched and samples 1021 
combined 1:1:1. The sample was vacuum-centrifuged to near dryness and subjected to C18 1022 
SPE (Sep-Pak, Waters). Six fractions generated using high pH reversed phase fractionation as 1023 
previously described (Nightingale et al., 2018) were analysed to increase the overall number 1024 
of peptides quantified. 1025 
Mass spectrometry data was acquired using an Orbitrap Lumos as previously described 1026 
(Nightingale et al., 2018). An Ultimate 3000 RSLC nano UHPLC equipped with a 300 µm ID 1027 
x 5 mm Acclaim PepMap µ-Precolumn (Thermo Fisher Scientific) and a 75 µm ID x 50 cm 1028 
2.1 µm particle Acclaim PepMap RSLC analytical column was used. Loading solvent was 1029 
0.1% FA, analytical solvent A: 0.1% FA and B: 80% MeCN + 0.1% FA. All separations were 1030 
carried out at 55°C. Samples were loaded at 5 µL/minute for 5 minutes in loading solvent 1031 
before beginning the analytical gradient. The following gradient was used: 3-7% B over 3 1032 
minutes, 7-37% B over 173 minutes, followed by a 4 minute wash at 95% B and equilibration 1033 
at 3% B for 15 minutes. Each analysis used a MultiNotch MS3-based TMT method 1034 
(McAlister et al., 2014). The following settings were used: MS1: 380-1500 Th, 120,000 1035 
Resolution, 2x10
5
 automatic gain control (AGC) target, 50 ms maximum injection time. 1036 
MS2: Quadrupole isolation at an isolation width of m/z 0.7, CID fragmentation (normalised 1037 
collision energy (NCE) 35) with ion trap scanning in turbo mode from m/z 120, 1.5x10
4
 AGC 1038 
target, 120 ms maximum injection time. MS3: In Synchronous Precursor Selection mode the 1039 
top 6 MS2 ions were selected for HCD fragmentation (NCE 65) and scanned in the Orbitrap 1040 
at 60,000 resolution with an AGC target of 1x10
5
 and a maximum accumulation time of 150 1041 
ms. Ions were not accumulated for all parallelisable time. The entire MS/MS/MS cycle had a 1042 
target time of 3 s. Dynamic exclusion was set to +/- 10 ppm for 70 s. MS2 fragmentation was 1043 
trigged on precursors 5x10
3
 counts and above. Data analysis is discussed below. 1044 
 1045 
 1046 
Transient transfection 1047 
7.5 x 10
5
 HEK293T cells were plated in each well of a 6-well dish 24 h prior to transfection. 1048 
A total of 2.5 µg plasmid DNA was transfected using TransIT-293 transfection reagent 1049 
(Mirus) according to the manufacturer's recommendations. Cell lysates were harvested 48 h 1050 
post-transfection as detailed below. 1051 
 1052 
Site-directed mutagenesis 1053 
A method based on PCR overlap extension was used to generate point mutations in the 1054 
coding sequence of NCK1. Primer sequences spanning the target region were generated 1055 
incorporating the desired sequence changes in both forward and reverse orientations. These, 1056 
along with primers that would anneal at the 5' and 3' ends of the full-length NCK1 coding 1057 
sequence (NCK1F and NCK1R, respectively) were used to amplify two fragments of NCK1, 1058 
each incorporating the point mutation. Fragments were purified and assembled into a full-1059 
length mutant NCK1 coding sequence by a second round of PCR using only NCK1F and 1060 
NCK1R. The product was then purified and subcloned as described above. A truncation 1061 
mutant of UL25 was generated by a single round of PCR using an appropriate internal 1062 
primer. 1063 
 1064 
Co-IP 1065 
HEK293T cells were used in all experiments. Cells were harvested and lysed in MCLB (50 1066 
mM Tris-HCl pH 7.5, 300 mM NaCl, 0.5% v/v NP40, 1 mM DTT and Roche protease 1067 
inhibitor cocktail). Samples were tumbled for 15 min at 4°C and then centrifuged at 16,100 g 1068 
for 15 min at 4°C. Lysates were then clarified by filtration through a 0.7 µm filter and 1069 
incubated for 3 h with immobilised mouse monoclonal anti-V5 agarose resin. Samples were 1070 
washed three times with lysis buffer, followed by two PBS pH 7.4 washes. Subsequently, 1071 
proteins bound to the anti-V5 resin were eluted once by adding 40 µl of 2.5 mg/ml V5 1072 
peptide (Alpha Diagnostic International) in PBS at 37°C for 30 min with agitation. Lysates 1073 
were reduced with 6X Protein Loading Dye (375 mM Tris-HCl pH 6.8, 12% w/v SDS, 30% 1074 
v/v glycerol, 0.6 M DTT, 0.06% w/v bromophenol blue) for 5 min at 95°C. 50 g of protein 1075 
for each sample was separated by PAGE using 4-15% TGX Precast Protein Gels (Bio-rad), 1076 
and then transferred to PVDF membranes using Trans-Blot Systems (Bio-rad). The following 1077 
primary antibodies were used: anti-Calnexin (CANX, LS-B6881, LifeSpan BioSciences), 1078 
anti-GAPDH (MAB5718, R&D Systems), anti-V5 (MA5-15253, Thermo), anti-HA (C29F4, 1079 
Cell Signaling), anti-CNOT2 (NBP2-56034, Novus), anti-CNOT7 (ab195587, Abcam), anti-1080 
NEDD4 (MAB6218, R&D Systems). Secondary antibodies were IRDye 680RD goat anti-1081 
mouse (925-68070, LI-COR), IRDye 680RD goat anti-rabbit (926-68071, LI-COR), IRDye 1082 
800CW goat anti-mouse (926-32210, LI-COR) and IRDye 800CW goat anti-rabbit (925-1083 
32211, LI-COR).  Fluorescent signals were detected using a LI-COR Odyssey, and images 1084 
were processed using Image Studio Lite (LI-COR). 1085 
 1086 
Viral growth curve analysis 1087 
For each virus stock, 1 × 10
6
 HFFF TERTs were seeded in duplicate T25 flasks in 1088 
DMEM/FBS/PS. After 24 h, the medium was changed to 1 ml DMEM containing the 1089 
requisite volume of HCMV strain Merlin stock to achieve MOI 1, and the cells were rocked 1090 
gently. After adsorption for 2 h at 37°C, unbound virus was removed by washing with 1091 
DMEM. Cells were then overlaid with 5 ml DMEM/FBS/PS. Every 48 h, all medium was 1092 
removed and replaced. 1 ml aliquots of removed media were retained for titration in 1093 
fibroblasts. Cells in these aliquots that had detached from the monolayer were pelleted by 1094 
centrifugation at 400 x g for 10 min at 18°C and discarded. Prior to titration, all supernatants 1095 
were stored at -70°C. 1096 
Titrations of cell-free virus were performed simultaneously in fibroblasts by flow cytometry, 1097 
using UL36-GFP expression as a marker to calculate the percentage of infection at 24 h PI.  1098 
 1099 
Data analysis 1100 
In the following description, the first report in the literature for each relevant algorithm is 1101 
listed. Mass spectra were processed using MassPike, which is a Sequest-based software 1102 
pipeline for quantitative proteomics, through a collaborative arrangement with Professor 1103 
Steven Gygi’s laboratory at Harvard Medical School. MS spectra were converted to mzXML 1104 
using an extractor built upon Thermo Fisher’s RAW File Reader library (version 4.0.26). 1105 
This software is a component of the MassPike software platform and is licensed by Harvard 1106 
Medical School. 1107 
 1108 
A combined database was constructed as described in (Nightingale et al., 2018)from (a) the 1109 
human Uniprot database (accessed 26 January 2017), (b) the HCMV strain Merlin Uniprot 1110 
database, (c) all additional non-canonical human cytomegalovirus proteins described by 1111 
Stern-Ginossar et al (Stern-Ginossar et al., 2012), (d) a six-frame translation of the HCMV 1112 
strain Merlin genome filtered to include all ORFs of ≥8 codons (delimited by stop codons 1113 
rather than requiring an initiating ATG codon), and (e) common contaminants such as 1114 
porcine trypsin and endoproteinase LysC. ORFs from the six-frame translation (6FT-ORFs) 1115 
were named as follows: 6FT_Frame_ORFnumber_length, where Frame is numbered 1-6, and 1116 
length is in amino acid residues. The combined database was concatenated with a reverse 1117 
database composed of all protein sequences in reversed order. Searches were performed using 1118 
a 20 ppm precursor ion tolerance (Haas et al., 2006). Product ion tolerance was set to 0.03 1119 
Th. Oxidation of methionine residues (15.99492 Da) was set as a variable modification. 1120 
Peptides were assumed to be fully tryptic with up to two missed cleavages. 1121 
 1122 
To control the fraction of erroneous protein identifications, a target-decoy strategy was 1123 
employed (Elias et al., 2007, 2010). Peptide spectral matches (PSMs) were filtered to an 1124 
initial peptide-level false discovery rate (FDR) of 1% with subsequent filtering to attain a 1125 
final protein-level FDR of 1% (Kim et al., 2011; Wu et al., 2011). PSM filtering was 1126 
performed using linear discriminant analysis as described previously (Huttlin et al., 2010). 1127 
Filtering was implemented in R using the linear discriminant analysis (LDA) function in the 1128 
package MASS (cran.r-project.org/web/packages/MASS). This distinguishes correct from 1129 
incorrect peptide identifications in a manner analogous to the widely used Percolator 1130 
algorithm (Kall et al., 2007), although employing a distinct machine-learning algorithm. The 1131 
following parameters were considered: XCorr, ΔCn, missed cleavages, peptide length, charge 1132 
state, and precursor mass accuracy. Peptides shorter than seven amino acids in length or with 1133 
XCorr less than 1.0 were excluded prior to LDA filtering. Peptides were then assembled into 1134 
proteins and the resulting protein IDs were scored probalistically and filtered to a 1% protein-1135 
level FDR. 1136 
 1137 
For MS3-based TMT, as previously described (Nightingale et al., 2018), TMT tags on lysine 1138 
residues and peptide N termini (229.162932 Da) and carbamidomethylation of cysteine 1139 
residues (57.02146 Da) were included as static modifications. Proteins were quantified by 1140 
summing TMT reporter ion counts across all matching peptide-spectral matches using 1141 
”MassPike”, as described previously (McAlister et al., 2014). Briefly, a 0.003 Th window 1142 
around the theoretical m/z of each reporter ion (126, 127n, 128n) was scanned for ions, and 1143 
the maximum intensity nearest to the theoretical m/z was used. An isolation specificity filter 1144 
with a cutoff of 50% was employed to minimise peptide co-isolation (McAlister et al., 2014). 1145 
Peptide-spectral matches with poor quality MS3 spectra (more than 3 TMT channels missing 1146 
and/or a combined S:N ratio of less than 100 across all TMT reporter ions) or no MS3 spectra 1147 
at all were excluded from quantitation. Peptides meeting the stated criteria for reliable 1148 
quantitation were then summed by parent protein, in effect weighting the contributions of 1149 
individual peptides to the total protein signal based on their individual TMT reporter ion 1150 
yields. Protein quantitation values were exported for further analysis in Excel. 1151 
For protein quantitation, reverse and contaminant proteins were removed, then each reporter 1152 
ion channel was summed across all quantified proteins and normalised assuming equal 1153 
protein loading across all channels. For further analysis and display in Figure 6G, fractional 1154 
TMT signals were used (i.e. reporting the fraction of maximal signal observed for each 1155 
protein in each TMT channel, rather than the absolute normalized signal intensity). This 1156 
effectively corrected for differences in the numbers of peptides observed per protein. 1157 
 1158 
 1159 
Interactor identification with CompPASS 1160 
To identify HCIPs for each bait, replicate pairs were combined to attain a summary of 1161 
proteins identified in both runs. Peptides within replicates were reassembled into proteins 1162 
following the principles of parsimony (Huttlin et al., 2010). Where all PSMs from a given 1163 
HCMV protein could be explained either by a canonical gene or a non-canonical ORF, the 1164 
canonical gene was picked in preference. In four cases (UL24/ORFL71C_(UL24), 1165 
UL31/ORFL87W_(UL31), UL150A/ORFL321W, UL44/ORFL112C_(UL44)), PSMs 1166 
assigned to a non-canonical ORF were a mixture of peptides from the canonical protein and 1167 
the ORF. This occurred where the ORF was a 5’-terminal extension of the canonical protein 1168 
(thus meaning that the smallest set of proteins necessary to account for all observed peptides 1169 
included the ORFs alone). In these cases, the peptides corresponding to the canonical protein 1170 
were separated from those unique to the ORF, generating two separate entries. 1171 
CompPASS scoring was performed as described previously (Huttlin et al., 2015), in two 1172 
analyses that were subsequently combined, one for NP40-based IPs and the other for 1173 
digitonin IPs. These data were treated separately to better model detergent-specific 1174 
differences in IP-MS background. Data reported for each protein in every IP in the dataset 1175 
include: (a) the number of peptide spectrum matches (PSMs) averaged between technical 1176 
replicates; (b) an entropy score, which compares the number of PSM between replicates to 1177 
eliminate proteins that are not detected consistently; (c) a z-score, calculated in comparison to 1178 
the average and standard deviation of PSMs observed across all IPs; and (d) an NWD score, 1179 
which reflects (i) how frequently this protein was detected and (ii) whether it was detected 1180 
reproducibly. NWD scores were calculated as described in (Behrends et al., 2010) using the 1181 
fraction of runs in which a protein was observed, the observed number of PSMs, the average 1182 
and standard deviation of PSMs observed for that protein across all IPs, and the number of 1183 
replicates (1 or 2) containing the protein of interest. NWD Scores were normalized so that the 1184 
top 2% earned scores ≥1.0. For NP40-based IPs, the top 2% of z-scores were >6.676, and for 1185 
digitonin-based IPs were >4.329. 1186 
As the set of digitonin-based IPs was necessarily smaller than NP40-based IPs (18 compared 1187 
to 153 viral genes examined respectively), additional control IPs were included. Biological 1188 
duplicates of cells transduced with empty vector controls (‘GAW control’), and biological 1189 
duplicates of cells transduced with a vector encoding green fluorescent protein (GFP) were 1190 
included in the digitonin set. A single replicate of the GAW control was included in the NP40 1191 
set. These controls had the effect of increasing the number of IPs that identified non-specific 1192 
interacting proteins, thus decreasing NWD and z-scores for these proteins. Mass spectrometry 1193 
RAW files from control UL123 IPs included to ensure batch-to-batch consistency were not 1194 
included in the final data analysis, to avoid modification of NWD and z-scores for the 1195 
infected UL123-expressing sample. 1196 
Following CompPASS analysis, a series of filters were applied to remove inconsistent and 1197 
low-confidence protein identifications across all IPs and minimize both false protein 1198 
identifications and associations. These included: (a) a minimum PSM score of 1.5 (i.e. a 1199 
minimum of 3 peptides per protein across both replicates); (b) a minimum entropy score of 1200 
0.75; (c) a top 2% NWD or z-score. Previous studies have estimated a 5% false discovery rate 1201 
when employing a similar strategy with a top 2% NWD score (Sowa et al., 2009). 1202 
Interactions passing these criteria are shown in Supplementary File 2B, and used in all 1203 
subsequent analyses throughout this work. As found in prior human interactome 1204 
investigations, certain known interactions fell just below the stringent top 2% NWD or z-1205 
score cutoffs. Proteins were therefore also included with top 5% NWD or z-scores (>0.434 1206 
and >3.688, respectively), if they had been reported to interact with the bait in a prior study 1207 
(Gallegos et al., 2016). For protein UL133 (2 TM regions), an initial digitonin-based AP-MS 1208 
analysis failed to generate any interactors after filtering. This IP was repeated using the 1209 
NP40-based lysis buffer. 1210 
For added stringency with baits solubilized in NP40, the supervised learning algorithm 1211 
CompPass Plus, was employed. This identifies HCIPs whilst minimising both false positive 1212 
protein IDs and background proteins as described previously (Huttlin et al., 2017). The 1213 
CompPass Plus model was trained using known HCMV protein interactions drawn from 1214 
BioGRID, IntAct, Uniprot, MINT, and Virus Mentha; incorrect protein IDs were modeled 1215 
using the target-decoy method. Results reported from this algorithm include p(Interactor), the 1216 
probability that a given prey is a specific interactor. We considered interactions that passed 1217 
CompPass filters, had p(Interactor) values of >0.75 from CompPass Plus and in which the 1218 
prey was identified by at least two unique peptides as a VHCIP. These are also indicated in 1219 
Supplementary File 2B.Cytoscape ver 3.7.1 was employed to display protein-protein 1220 
interactions (Shannon et al., 2003). 1221 
 1222 
IBAQ analysis 1223 
The intensity-based absolute quantification (IBAQ) method was adapted from the original 1224 
description (Schwanhausser et al., 2011) for two independent whole cell analyses of wild-1225 
type (WT) HCMV strain Merlin infection at 24, 48 and 72 h PI. These included: (a) WCL3 1226 
from (Weekes et al., 2014) (conditions examined were 0, 24, 48, 72, 96 h PI with WT Merlin 1227 
with or without the viral DNA synthesis inhibitor phosphonoformate); (b) proteomic series 3 1228 
from (Fielding et al., 2017) (0, 24, 48, 72 h PI with WT Merlin with or without the lysosomal 1229 
inhibitor leupeptin, or with an HCMV recombinant having a block deletion in the US12-1230 
US21 region). The maximum MS1 precursor intensity for each quantified peptide was 1231 
determined for each experiment, and a summed MS1 precursor intensity for each protein 1232 
across all matching peptides was calculated. To determine the proportion of the summed 1233 
intensity that arose at 24, 48 and 72 h PI, the summed intensity was adjusted in proportion to 1234 
normalized TMT values: (24h + 48 h + 72 h PI) / ∑(all quantified times or conditions). 1235 
Adjusted intensities were divided by the number of theoretical tryptic peptides from each 1236 
protein between 7 and 30 amino acid residues in length to give an estimated IBAQ value. The 1237 
same calculation was used to estimate IBAQ abundances for viral proteins (Supplementary 1238 
File 1A, columns C-E) and human proteins (Supplementary File 1C columns E-G). Viral 1239 
and human IBAQ values in these columns can be directly compared to examine the relative 1240 
abundances of HCMV and host proteins. 1241 
Where PSMs had been assigned to a non-canonical viral ORF but were redundant to a 1242 
canonical viral protein, peptides corresponding to the canonical protein were separated from 1243 
those unique to the ORF, generating two separate entries as described in ‘Interactor 1244 
Identification with CompPASS’. For the non-canonical ORF, the number of theoretical 1245 
peptides from the non-canonical protein fragment were used in the IBAQ calculation. 1246 
Values were separately normalized for HCMV and human proteins by the sum of all IBAQ 1247 
values within each experiment, and average and range of the normalized values calculated 1248 
and plotted (Figure 1 – Figure Supplement 1A, Supplementary File 1A columns F-I, 1249 
Supplementary File 1C columns H-K). 1250 
 1251 
Interaction Database Comparisons 1252 
For purposes of comparison, lists of physical interactions between viral proteins and human 1253 
proteins were downloaded in October 2018 from: BioGRID (Chatr-Aryamontri et al., 2013), 1254 
IntAct (Orchard et al., 2014), Uniprot (www.uniprot.org), MINT (Licata et al., 2012), and 1255 
Virus Mentha (Calderone et al., 2015). 1256 
 1257 
Domain association analysis 1258 
Domain enrichments were calculated by mapping Pfam domains drawn from Uniprot onto 1259 
human and HCMV amino acid sequences. The total number of interactions that included each 1260 
domain, and the number of interactions involving pairs of domains whose parent proteins 1261 
associate, were counted. The significance of the association among co-occurring domains 1262 
was calculated using Fisher’s Exact Test as described previously (Huttlin et al., 2015). p-1263 
values were corrected for multiple hypothesis testing (Benjamini et al., 1995). Domains were 1264 
considered significantly associated if their adjusted p-value was <0.01. Overall 96 domains 1265 
have been identified in HCMV proteins by Pfam, however only 10 domains were identified 1266 
in two or more baits. Only this subset was examined in Figure 4A and Supplementary File 1267 
5 to increase confidence in domain association predictions. 1268 
 1269 
Statistical analysis 1270 
Figures 2, Figure 2 - Supplement 1 Benjamini-Hochberg adjusted p-values for enrichment 1271 
are shown as blue surrounds to each pathway where p<0.05. More significantly enriched 1272 
pathways are shown in darker blue as detailed in the figures. 1273 
Figure 4 The significance of the association among co-occurring domains was 1274 
calculated using Fisher’s Exact Test as described previously (Huttlin et al., 2015). p-values 1275 
were corrected for multiple hypothesis testing. 1276 
Figure 5 (B) Benjamini-Hochberg adjusted Significance A values were used to estimate 1277 
p-values in the top panels; **p<0.005, ***p<0.0005. Mean and SEM are shown for transcript 1278 
quantitation (n=3) in the middle panels. A p-value for the difference between rates of 1279 
degradation is shown in the bottom panel; ***p<0.0005. All calculations and statistics are 1280 
described in (Nightingale et al., 2018). (F) Mean and SEM are shown for transcript 1281 
quantitation as in (B). 1282 
Figure 6 (F) p-values for a difference between wild-type and ORFL147C-deficient 1283 
virus were estimated using a two-tailed Student’s t-test. ***p<0.001, ****p<0.0001. 1284 
Figure 7 Benjamini-Hochberg adjusted p-values are shown for each enriched pathway. 1285 
Figure 1 – Figure Supplement 1  Average IBAQ values +/- range are plotted for proteins 1286 
quantified in both analyses (n=2). 1287 
 1288 
 1289 
Pathway analysis 1290 
The Database for Annotation, Visualisation and Integrated Discovery (DAVID) version 6.8 1291 
was used to determine pathway enrichment for Figures 2 and Figure 2 – Figure 1292 
Supplement 1, 2A (Huang da et al., 2009), in which all human HCIPs for all viral baits were 1293 
searched against a background of all human proteins, using default settings. For Figures 6C 1294 
and Figure 4 – Figure Supplement 1, DAVID and Reactome software (Fabregat et al., 1295 
2018) were used to analyse 80 human HCIPs interacting with ORFL147C compared to all 1296 
human proteins as background. 1297 
To identify type I interferon-stimulated genes (ISG) for Figure 3D, gene symbols were 1298 
searched in ‘Interferome 2.0’ (http://interferome.org/interferome/home.jspx) (Rusinova et al., 1299 
2013). A gene was considered to be an ISG if it was upregulated at least 2-fold by type I 1300 
interferon in at least two independent experiments in human cells. 1301 
 1302 
Data Availability 1303 
The mass spectrometry proteomics data have been deposited to the ProteomeXchange 1304 
Consortium (http://www.proteomexchange.org/) via the PRIDE (Vizcaino et al., 2016) 1305 
partner repository with the dataset identifier PXD014845. 1306 
 1307 
FIGURE LEGENDS 1308 
 1309 
Figure 1. Schematic of the IP strategy. 1310 
IP samples were generated and analysed in technical duplicate, using the method originally 1311 
described in (Huttlin et al., 2017; Huttlin et al., 2015) and discussed in detail in the Materials 1312 
and Methods section. For 153 baits with zero or one transmembrane (TM) region predicted 1313 
by Uniprot, an NP40-based lysis buffer was used; for 18 baits with >1 TM region, a 1314 
digitonin-based buffer was used, as this has previously been demonstrated to improve 1315 
identifications of interacting proteins (‘prey’) (Babu et al., 2012) (Supplementary File 1B). 1316 
Each dataset was scored separately using the CompPASS algorithm (Huttlin et al., 2015; 1317 
Sowa et al., 2009) to better model detergent-specific variation in IP-MS background. Data 1318 
reported for each prey protein in every IP includes: (a) the number of peptide spectral 1319 
matches (PSMs), averaged between technical replicates; (b) an entropy score, which 1320 
compares the number of PSM between replicates to eliminate proteins that are not detected 1321 
consistently; (c) a z-score, calculated in comparison to the average and standard deviation of 1322 
PSMs observed across all IPs; and (d) a normalized WD (NWD) score. The NWD score 1323 
addresses whether (i) the protein is detected across all IPs, and (ii) whether it is detected 1324 
reproducibly among replicates. It was calculated as described in (Behrends et al., 2010) using 1325 
the fraction of runs in which a protein was observed, the observed number of PSMs, the 1326 
average and standard deviation of PSMs observed for that protein across all IPs, and the 1327 
number of replicates (1 or 2) containing the protein of interest. NWD scores were normalized 1328 
so that the top 2% earned scores of ≥1.0. Stringent filters were applied to remove inconsistent 1329 
and low-confidence protein identifications across all IPs and thus minimize both false protein 1330 
identifications and associations (Huttlin et al., 2015). These included: (a) a minimum PSM 1331 
score of 1.5 (i.e. ≥3 peptides per protein across both replicates); (b) an entropy score of 1332 
≥0.75; and (c) an NWD or z-score in the top 2%. Previous studies have estimated a 5% false 1333 
discovery rate when employing a similar strategy with a top NWD score cutoff of 2% (Sowa 1334 
et al., 2009). Interactions passing these criteria are named ‘high confidence interacting 1335 
proteins’ (HCIPs) (Supplementary File 2B), and were used in all subsequent analyses. For 1336 
added stringency, the supervised learning algorithm CompPass Plus was employed. This 1337 
additionally assessed batch variations, overall spectral counts, unique peptide counts and 1338 
protein detection frequency. Shannon entropy quantified a protein’s consistency of detection 1339 
across technical duplicate LC-MS analyses, removing inconsistent protein identifications 1340 
(Huttlin et al., 2017). CompPass plus was developed for interactomes with ≥96 baits and in 1341 
the present study was only applied to the 153 baits solubilized in NP40. Interactions that 1342 
passed CompPass filters, had CompPass Plus p(Interactor)>0.75 and in which the prey was 1343 
identified by ≥2 unique peptides were considered as very high confidence interacting proteins 1344 
(VHCIPs). These are indicated in green shading in Supplementary File 2B. To facilitate 1345 
global analysis of all data, and because digitonin-solubilised interactions were not analysed 1346 
using CompPass plus, HCIPs as opposed to VHCIPs were examined for the remainder of this 1347 
study. The identification of an interacting protein as a VHCIP nevertheless adds additional 1348 
confidence that the interaction observed is likely to be genuine. 1349 
 1350 
Figure 1 – Figure Supplement 1. Further details of the interactome. 1351 
(A) Abundance of 127 quantified canonical and non-canonical HCMV ORFs. The 1352 
intensity-based absolute quantification (IBAQ) method was adapted for data from two 1353 
whole cell analyses of HCMV infection at 24, 48 and 72 h PI (Fielding et al., 2017; 1354 
Weekes et al., 2014) as described in the Materials and Methods section. Normalised 1355 
average IBAQ values +/- range are plotted for proteins quantified in both analyses. 1356 
Data is split across two graphs to improve legibility. For proteins only quantified in 1357 
one of the two analyses, data are shown in Supplementary File 1A. ORFL147C was 1358 
the most abundant non-canonical ORF, and ORFS343C.iORF1 (referred to in the 1359 
manuscript as ORFS343C) was one of the least abundant non-canonical ORFs (shown 1360 
in red). Both were included as baits in the interactome. 1361 
(B) Proportion of baits whose expression was verified by IB, MS or RT-qPCR (see also 1362 
Supplementary File 1B). Experiments were performed in advance of the interactome 1363 
study, using uninfected lysates to validate bait expression. MS was used if the bait 1364 
was not detected by IB, and RT-qPCR was used if the bait was not identified by MS. 1365 
Expression of 78% of baits was further validated in the interactome itself, including 1366 
9/18 baits initially only observed by RT-qPCR. These nine baits were included in the 1367 
‘detected by MS’ category. For the nine baits whose expression was only ever 1368 
observed by RT-qPCR, four were small proteins of 47-111 amino acids, with 1-4 1369 
theoretically observable peptides. None of these four proteins were previously 1370 
detected in two systematic proteomic analyses of HCMV infection (Nightingale et al., 1371 
2018; Weekes et al., 2014). In the same studies, a further 4/9 viral proteins were only 1372 
detected by a median of 0-2 peptides, and 2/4 had multiple transmembrane domains, 1373 
suggesting that detection may have been limited by protein abundance or 1374 
hydrophobicity. Nevertheless, known protein prey of these nine viral baits were 1375 
detected in the interactome, for example the interaction between the small capsomere-1376 
interacting protein UL48A and major capsid protein UL86, and membrane protein 1377 
US18 and natural killer cell cytotoxicity receptor 3 ligand 1 (NCR3LG1) 1378 
(Supplementary File 3, (Fielding et al., 2017). Data for the nine baits that were only 1379 
validated by RT-qPCR was therefore included in this interactome. Only expression of 1380 
UL136 could not be validated by any method, despite the use of primers that 1381 
recognized both a short and full-sized amplicon (Supplementary File 1E) and this 1382 
bait was excluded from further analysis. 1383 
(C) Correlation of the number of total, unique and bait peptides from each protein 1384 
identified in replicates 1 and 2. ‘Unique peptides’ refers to peptides that exist only in 1385 
one protein from the human or HCMV proteomes. ‘Bait peptides’ refer to peptides 1386 
derived from the bait protein for each IP (i.e. from US1 in the US1 IP; from UL29 in 1387 
the UL29 IP etc). All data for this figure are also shown in 1388 
Figure_1_Figure_Supplement_1 - source data 1. 1389 
(D) Reproducibility of interactome analyses. In this interactome, as previously described 1390 
(Huttlin et al., 2015), biological replicates were pooled and samples analysed in 1391 
technical duplicate to solve certain technical issues. Specifically, due to the potential 1392 
for carry-over of peptides between adjacent injections of different IP samples (even 1393 
with two washes between each sample), it was necessary to use consistency of 1394 
detection of prey as a measure of confidence in bait-prey interaction. To electronically 1395 
filter out carry-over contaminants, an entropy score (described in ‘Data analysis’ in 1396 
Materials and Methods) compared the number of peptide-spectrum matches (PSM) 1397 
between replicate injections and eliminated prey that were not detected consistently. It 1398 
was therefore important that replicate injection material was as similar as possible to 1399 
ensure that this filter was efficacious (see also Materials and Methods). The 1400 
CompPass algorithm (Huttlin et al., 2015; Sowa et al., 2009) was developed based on 1401 
this specific protocol. To gain a measure of variability between biological replicate 1402 
samples, six IP-MS experiments were repeated with independent analysis of each 1403 
biological replicate. In this figure, PSM are shown for HCIPs predicted by the 1404 
interactome for each of the baits. For example, the interactome predicted four HCIPs 1405 
for RL1: CUL4A, CUL4B, DDA1 and RL1 itself (Figure 2, Supplementary File 1406 
2B). All data for this figure are also shown in Figure_1_Figure_Supplement_1 - 1407 
source data 2. 1408 
(E) Viral proteins expressed at 60 h PI. Profiles of typical viral proteins from each of five 1409 
temporal classes Tp1-Tp5 are shown (adapted from (Weekes et al., 2014)). At 60 h PI, 1410 
peptides from 139/139 quantified canonical HCMV proteins and 14/14 quantified 1411 
non-canonical ORFs were detected. 1412 
 1413 
Figure 1 – Figure Supplement 2. Further details of interactions. 1414 
(A) Number of HCIPs per bait excluding bait-bait interactions. Four graphs with different 1415 
x-axis scales illustrate the range of interacting viral or cellular proteins per bait. 1416 
Gridlines are displayed at each log interval. Full data is shown in Supplementary 1417 
File 2A. 1418 
(B) Validation of the interactome data from BioGRID, IntAct, Uniprot, MINT, and Virus 1419 
Mentha (Calderone et al., 2015; Chatr-Aryamontri et al., 2013; Licata et al., 2012; 1420 
Orchard et al., 2014). 167 virus-virus and virus-host interactions were identified from 1421 
these databases. Of these, 127 were identified in unfiltered data from the HCMV 1422 
interactome, and 59 passed the stringent scoring thresholds employed (see also 1423 
Supplementary File 3). Full details of all HCIPs are given in Supplementary File 2. 1424 
 1425 
Figure 2. Systematic analysis of interactome data predicts novel functions for viral 1426 
proteins. DAVID software with default settings (Huang da et al., 2009) was applied to 1427 
determine which pathways were enriched amongst all HCIPs in the interactome, in 1428 
comparison to all human proteins as background. Benjamini-Hochberg adjusted p-values are 1429 
shown as blue surrounds to each pathway enriched at p<0.05. Viral baits are linked to 1430 
enriched pathways where >33% of human interacting proteins belonged to a given pathway, 1431 
and examples are shown around the outside of the figure. These examples are indicated in the 1432 
central part of the figure by purple shading. For example, 6/9 (67%) human HCIPs for UL43 1433 
were part of the 14-3-3 protein. Viral baits are shown as large turquoise circles, and 1434 
interacting viral proteins as smaller turquoise circles. Members of enriched pathways are 1435 
shown in orange or yellow (for NuRD complex and histone deacetylation, protein 1436 
membership of both pathways is indicated by half-orange, half-yellow circles). Solid lines 1437 
indicate interactions identified by this interactome, and dashed lines indicated interactions 1438 
derived from human Bioplex 2.0 and subsequent unpublished data ((Huttlin et al., 2017) and 1439 
http://bioplex.hms.harvard.edu/downloadInteractions.php). Full data are shown in 1440 
Supplementary File 4. As an alternative approach to highlight cellular functions that 1441 
predominantly related to individual viral proteins, Figure 2 – Figure Supplement 1 shows 1442 
pathways with p<0.05 (after Benjamini-Hochberg adjustment) and for which >33% of the 1443 
identified cellular protein members of the pathway interacted with a given viral bait. 1444 
 1445 
Figure 2 – Figure Supplement 1. Pathways enriched with p<0.05 (after Benjamini-1446 
Hochberg adjustment) and for which >33% of the identified components interacted with a 1447 
given viral bait. For example, all members of the thick filament/muscle myosin complex 1448 
detected in this interactome interacted with US28 (100%). For the bottom three complexes 1449 
(UL74, US27 and UL132), each viral bait interacted with a total of 52-107 proteins. For 1450 
simplicity, only members of the illustrated pathway identified in this interactome are 1451 
displayed. For example, 14 members of the SNARE complex were enriched in the 1452 
interactome, of which 9 interacted with US27 (64%). Green circles show members of a 1453 
pathway that were detected in the interactome but did not interact with the bait. Other 1454 
colouring is shown as described in the legend to Figure 2. 1455 
 1456 
Figure 2 – Figure Supplement 2. Further details of interactions according to viral protein 1457 
temporal class. 1458 
(A) Functional enrichment of host HCIPs for each temporal class of viral bait. DAVID 1459 
software with default settings (Huang da et al., 2009) was applied to determine which 1460 
pathways were enriched amongst human HCIPs of each of the Tp1-Tp5 classes of 1461 
bait, in comparison to all human HCIP as background. Benjamini-Hochberg adjusted 1462 
p-values are shown on the x-axis. 1463 
(B) Temporal analysis of viral-viral protein interactions. The contingency table shows 71 1464 
viral protein-protein interactions for which both bait and prey had a defined Tp class 1465 
(from (Weekes et al., 2014)). 1466 
 1467 
Figure 3. Validation of interactome data by co-IP. 1468 
(A) Co-IPs validating that UL72 interacts with CCR4-NOT Transcription Complex 1469 
Subunits 7 and 2 (CNOT7 and CNOT2), conducted in HEK293T cells. For all 1470 
experiments in this figure, left panels show an IB of 1-2% of input sample, and 1471 
right panels shown an anti-V5 co-IP. Cells were transiently transfected with two 1472 
plasmids, one expressing the C-terminally V5-tagged viral protein and the other 1473 
expressing the C-terminally HA-tagged cellular prey. Bait proteins were detected 1474 
with anti-V5, and prey with antibodies against CNOT7 or CNOT2 protein. 1475 
Controls included GFP or the viral UL34 protein. CANX – calnexin loading 1476 
control. This figure is representative of n= 1 experiment (CNOT2); n=2 1477 
experiments (CNOT7). Expected sizes: CNOT7: 33kDa; CNOT2: 52kDa; 1478 
CANX: 72kDa; UL72: 44kDa; UL34: 45kDa. 1479 
(B) Co-IPs validating that UL72 interacts with CNOT7 and CNOT2, conducted in 1480 
HFFF-TERT cells overexpressing C-terminally V5-tagged UL72. Proteins were 1481 
detected as described in (A). This figure is representative of n= 2 experiments 1482 
(CNOT2); n=1 experiment (CNOT7). Expected sizes: CNOT7: 33kDa; CNOT2: 1483 
52kDa; CANX: 72kDa; UL72: 44kDa; UL34: 45kDa. 1484 
(C) Co-IP validating the interaction between RL1 and CUL4A, conducted in 1485 
HEK293T cells as described in (A), but with detection of CUL4A using anti-HA. 1486 
This figure is representative of n= 4 experiments. Expected sizes: CUL4A: 1487 
77kDa; RL1: 35kDa; UL34: 45kDa; CANX: 72kDa. 1488 
(D) HCMV UL71 interacted with multiple interferon-stimulated proteins, including 1489 
TRIM22.  1490 
(E) Co-IP validating the interaction between UL71 and TRIM22, conducted as 1491 
described in (C). This figure is representative of n= 3 experiments. Expected 1492 
sizes: TRIM22: 56kDa; UL71: 40kDa; UL34: 45kDa; CANX: 72kDa. 1493 
 1494 
Figure 4. Interaction between UL25 and NCK1 identified by domain association 1495 
analysis. 1496 
(A) Table depicting significant associations between domains present in HCMV baits 1497 
(top) and human or viral prey (side). Pfam domains were mapped onto every bait and 1498 
prey protein in the interactome (Finn et al., 2014). The numbers of interactions 1499 
emanating from proteins containing each domain were tallied individually, along with 1500 
the numbers of interactions linking each observed domain pair. Contingency tables 1501 
were then populated to relate domain associations. For each pair, Fisher’s exact test 1502 
determined the likelihood of a non-random association. p values were adjusted for 1503 
multiple hypothesis testing (Benjamini et al., 1995). Coloured boxes identify domain 1504 
pairs that associate at a 1% false discovery rate (FDR). Red boxes indicate domain 1505 
pairs from this analysis discussed in the text. Domain associations are only shown for 1506 
domains occurring in at least two viral proteins. Supplementary File 5 shows the full 1507 
underlying data. 1508 
(B) All HCIPs for UL25 and a subset of HCIPs for UL26 (full data are shown in Figure 4 1509 
– Figure Supplement 1). DAVID analysis identified that members of the C-terminal 1510 
to LisH (CTLH) complex and COPII vesicle coat proteins were enriched among 1511 
UL26 HCIPs (Figure 2 – Figure Supplment 1). Domain association analysis 1512 
suggested that interaction of UL26 with CTLH components may occur via interaction 1513 
of the viral US22 domain with either cellular CLTH or LisH domains 1514 
(Supplementary File 5). Dashed lines represent human-human interactions derived 1515 
either from Bioplex 2.0 as described in Figure 2 or from curated or experimental data 1516 
in the STRING database. CPSF - Cleavage and polyadenylation specificity factor. 1517 
(C) Schematic of NCK1 and UL25 protein structures, indicating the position of point 1518 
mutations or truncation for (D). 1519 
(D) Co-IP demonstrating that the UL25 proline-rich C-terminal domain associates with 1520 
the first NCK1 SH3 domain, conducted as described in Figure 3. HEK293T cells 1521 
were transiently transfected with the indicated plasmids, one expressing the C-1522 
terminally V5-tagged viral protein and the other expressing C-terminally HA-tagged 1523 
NCK1. These proteins were detected with anti-V5 and anti-HA. Mutations or 1524 
truncations of each gene are indicated in the figure and in (C). GAPDH – loading 1525 
control. This figure is representative of n= 3 experiments. Expected sizes: NCK1: 1526 
43kDa; UL25: 74kDa; UL26: 21kDa; GAPDH: 36kDa. 1527 
 1528 
Figure 4 – Figure Supplement 1. Full interaction data for UL25 and UL26, annotated as 1529 
described in Figure 4B. 1530 
 1531 
Figure 5. UL42 identified as a hub of E3 destruction by a combination of interactome and 1532 
degradation data. US10 interacts with LRFN3, which is rapidly downregulated from the PM 1533 
during HCMV infection. 1534 
(A) High-confidence cellular interactors of UL42. 57% of UL42 interactors exhibited 1535 
ubiquitin protein transferase activity (Figure 2, counting NEDD4 only once). UL42 1536 
interacted with NEDD4, NEDD4 isoform 4 and NEDD4L, in addition to HECT, C2 1537 
and WW Domain Containing E3 Ubiquitin Protein Ligases HECW1 and 2. NEDD4-1538 
4: isoform 4 of NEDD4. 1539 
(B) ITCH, NEDD4 and NEDD4L are degraded during early HCMV infection (data from 1540 
(Nightingale et al., 2018)). Protein degradation was measured using three orthogonal 1541 
tandem mass tag (TMT)-based proteomic screens. The first measured protein 1542 
abundance throughout early infection in the presence or absence of inhibitors of the 1543 
proteasome or lysosome. The second compared transcript and protein abundance over 1544 
time to distinguish between degraded and transcriptionally regulated proteins. The 1545 
third employed an unbiased global pulse-chase to compare the rates of protein 1546 
degradation during HCMV infection against mock infection (NEDD4 and NEDD4L 1547 
were not quantified in this latter screen). Benjamini-Hochberg adjusted Significance 1548 
A values were used to estimate p-values in the top panels; **p<0.005, ***p<0.0005. 1549 
Mean and SEM are shown for transcript quantitation (n=3) in the middle panels. A p-1550 
value for the difference between rates of degradation is shown in the bottom panel; 1551 
***p<0.0005. All calculations and statistics are described in (Nightingale et al., 1552 
2018). 1553 
(C) UL42 transcript is expressed contemporaneously with NEDD4 and NEDD4L 1554 
degradation. Protein profiles from Figure 5B (red colour, (Nightingale et al., 2018)) 1555 
are overlaid with a UL42 transcript profile (blue colour, (Stern-Ginossar et al., 2012)). 1556 
UL42 transcript was not detected in our previous RNAseq analysis (Nightingale et al., 1557 
2018). 1558 
(D) Validation of interaction between UL42 and NEDD4 (left panel) and NEDD4L (right 1559 
panel) by co-IP, conducted as described in Figure 3. HEK293T cells were transiently 1560 
transfected with the indicated plasmids, one expressing the C-terminally V5-tagged 1561 
viral protein and the other expressing C-terminally HA-tagged NEDD4 or NEDD4L. 1562 
These proteins were detected with anti-V5 and anti-HA. This figure is representative 1563 
of n= 2 experiments (NEDD4); n=1 experiment (NEDD4L). Expected sizes: NEDD4: 1564 
104-149kDa; NEDD4L: 96-111kDa; UL42: 14kDa; UL34: 45kDa; CANX: 72kDa. 1565 
(E) UL42 was sufficient to degrade NEDD4. HFFF-TERTs expressing UL42 or controls 1566 
were lysed and immunoblotted as indicated. Anti-NEDD4 was used to detect 1567 
endogenous NEDD4. This figure is representative of n= 1 experiment. Expected sizes: 1568 
NEDD4: 104-149kDa; UL42: 14kDa; UL34: 45kDa; CANX: 72kDa. 1569 
(F) LRFN3 was rapidly downregulated from the PM during HCMV infection, in the 1570 
presence of upregulated transcript (mean and SEM are shown for transcript 1571 
quantitation (n=3); data are from (Nightingale et al., 2018)). 1572 
(G) HCIPs of US10, including LRFN3. 1573 
(H) Validation of the interaction between US10 and LRFN3 by co-IP, conducted as 1574 
described in Figure 3. Prey were detected using anti-HA. This figure is representative 1575 
of n= 2 experiments. Expected sizes: LRFN3: 66kDa; US10: 21kDa; UL34: 45kDa; 1576 
CANX: 72kDa. 1577 
 1578 
Figure 5 – Figure Supplement 1. Validation of interaction between UL42 and NEDD4 (left 1579 
panel) and NEDD4L (right panel) by co-IP, conducted as described in Figure 3. HEK293T 1580 
cells were transiently transfected with the indicated plasmids, one expressing N-terminally 1581 
V5-tagged UL42 and the other expressing C-terminally HA-tagged NEDD4 or NEDD4L. 1582 
These proteins were detected with anti-V5 and anti-HA. This figure is representative of n= 1 1583 
experiments. Expected sizes: NEDD4: 104-149kDa; NEDD4L: 96-111kDa; UL42: 14kDa; 1584 
CANX: 72kDa. 1585 
 1586 
Figure 6. HCMV ORFL147C interactors function in RNA binding, splicing and 1587 
transcription. 1588 
(A) Diagram of the ORFL147C coding sequence and relation to neighbouring viral 1589 
genes. 1590 
(B) Expression kinetics of ORFL147C, taken from (Weekes et al., 2014). Data was 1591 
taken from experiments WCL2 and WCL3, enabling assessment of 24, 48, 72 and 1592 
96 h time points in biological duplicate. Error bars show range. Mean expression 1593 
was normalized to a maximum of 1. 1594 
(C) Enrichment analysis of 80 human HCIPs interacting with ORFL147C. (i) DAVID 1595 
analysis using all human proteins as background. Benjamini-Hochberg adjusted p-1596 
values are shown. (ii) Reactome database analysis (Fabregat et al., 2018) showing 1597 
results with a minimum of 4 entities per enriched pathway. Full details of 1598 
interacting proteins are given in Supplementary File 7A-B. 1599 
(D) A subset of HCIPs for ORFL147C (full data is shown in Figure 6 – Figure 1600 
Supplement 1). Dashed lines represent human-human interactions derived from 1601 
Bioplex 2.0 as described in Figure 2, in addition to known interactions that had 1602 
been experimentally determined or derived from curated data as part of the 1603 
STRING database. 1604 
(E) Validation of interaction between ORFL147C and MBNL1 and CELF1 by co-IP, 1605 
conducted as described in Figure 3. HEK293T cells were transiently transfected 1606 
with the indicated plasmids, one expressing the C-terminally V5-tagged viral 1607 
protein and the other expressing C-terminally HA-tagged MBNL1 or CELF1. 1608 
These proteins were detected with anti-V5 and anti-HA. GAPDH – calnexin 1609 
loading control. This figure is representative of n= 1 experiment. Expected sizes: 1610 
MBNL1: 33-42kDa; CELF1: 50-55kDa; ORFL147C: 50kDa; UL25: 74kDa; 1611 
GAPDH: 36kDa. 1612 
(F) Growth analysis of an ORFL147C-deficient recombinant. The ORFL147C and 1613 
wild-type viruses were HCMV strain Merlin recombinants in which the enhanced 1614 
GFP (eGFP) gene was cloned as a 3’-terminal fusion with immediate-early gene 1615 
UL36, with a self-cleaving P2A peptide releasing the reporter following synthesis. 1616 
Insertion of GFP does not impede UL36 function in such recombinants 1617 
(Nightingale et al., 2018). Cells were infected at a MOI of 1, and supernatants 1618 
harvested and titred every two days. Cells were infected in biological duplicates, 1619 
and each supernatant was titred in technical duplicates. Mean values are shown, 1620 
and error bars represent SD. p-values for a difference between wild-type and 1621 
ORFL147C-deficient virus were estimated using a two-tailed Student’s t-test. 1622 
***p<0.001, ****p<0.0001. This figure is representative of n= 2 experiments. All 1623 
data for this figure are also shown in Figure_6 - source data 1. 1624 
(G) ORFL147C protein is not expressed during infection with the ORFL147C-1625 
deficient recombinant (MOI = 2, 48 h post infection). Viral protein expression 1626 
was analysed using tandem mass tag-based proteomics as previously described 1627 
(Nightingale et al., 2018). ORFL147C protein was measured at the same level as 1628 
during mock infection in cells infected with the ORFL147C-deficient 1629 
recombinant, attributable to noise. All data for this figure are also shown in 1630 
Figure_6 - source data 2. 1631 
 1632 
Figure 6 – Figure Supplement 1. Further details of ORFL147C interactions, and 1633 
construction of the ORFL147C virus. 1634 
(A) Full interaction data for ORFL147C, annotated as described in Figure 4B. 1635 
(B) Construction of a viral ORFL147C deletion mutant. The three most N-terminal 1636 
methionines in ORF147C were mutated without affecting the amino acid 1637 
sequences coded by UL56. The N-terminal protein sequences of ORFL147C and 1638 
UL56 are shown, in addition to corresponding coding sequences in the region of 1639 
the mutations. 1640 
 1641 
Figure 7. Overlap in functions targeted by different viruses. 1642 
(A) DAVID analysis of pathway enrichment among 176 HCIPs that interacted both 1643 
with HCMV baits (this study) and KSHV baits (Davis et al., 2015), in comparison 1644 
to all human proteins as background. Benjamini-Hochberg adjusted p-values are 1645 
shown for each pathway. Full details of interacting viral and host proteins are 1646 
given in Supplementary File 7A. 1647 
(B) DAVID analysis of pathway enrichment among HCIPs that only interacted with 1648 
HCMV but not KSHV baits, in comparison to all human proteins as background. 1649 
As the KSHV interactome was performed in HEK293T cells as opposed to 1650 
HFFFs, the list of HCMV HCIPs was first filtered to include proteins that were 1651 
clearly detectable in HEK293Ts, using the list of ~50,000 unfiltered bait-prey 1652 
interactions from KSHV to indicate protein expression (Davis et al., 2015). 1653 
Subsequently, both high confidence interacting prey of KSHV baits, and first 1654 
degree interactors of these prey from the human interactome, were excluded 1655 
(Huttlin et al., 2017), to leave a list of proteins that only interacted with HCMV. 1656 
Benjamini-Hochberg adjusted p-values are shown for each pathway. Full details 1657 
of interacting viral and host proteins are given in Supplementary File 7B. 1658 
 1659 
SUPPLEMENTARY FILE LEGENDS 1660 
 1661 
Supplementary File 1. Details of the interactome. (A) Relative abundance of all canonical 1662 
and non-canonical viral proteins quantified in experiment whole cell lysate 3 (WCL3) from 1663 
(Weekes et al., 2014) and whole cell lysate series 3 from (Fielding et al., 2017). Further 1664 
details of the calculations employed are given in Figure 1 – Figure Supplement 1A and the 1665 
Materials and Methods section. (B) Details of all 172 baits. Bait expression was verified by 1666 
IB, MS or RT-qPCR (Figure 1 – Figure Supplement 1B). (C) Relative abundance of all 1667 
human proteins expressed in HFFFs, calculated as described in (A). The ‘rank’ column 1668 
indicates the ranked average IBAQ abundance. The most abundant protein calculated by this 1669 
method was ranked 1, and least abundant ranked 8129. (D) Coding sequences of all viral 1670 
genes used in this study. A six base-pair linker region, a V5 tag then a stop codon directly 1671 
followed each sequence (Key Resources Table). Codon usage was optimised for expression 1672 
for US14, US17 and UL74. (E) Oligonucleotides and templates employed in the generation 1673 
and RT-qPCR of each viral vector. (F) Oligonucleotides and templates employed in the 1674 
generation and RT-qPCR of each human overexpression vector. 1675 
 1676 
Supplementary File 2. Full interactome data. (A) Numbers of HCIPs per bait, excluding 1677 
bait-bait interactions. (B) HCIPs for each bait (see Figure 1 and the Materials and Methods 1678 
section for details of the filtering employed, and the scores shown in this table). For baits 1679 
solubilized in NP40, VHCIPs are shown in green. The ‘Prey IBAQ rank’ column shows the 1680 
ranked IBAQ abundance from Supplementary File 1C, and gives an indication of how 1681 
abundant each prey protein was in infected HFFFs. A range of ranks is shown where more 1682 
than one isoform of a protein could be detected, in order to reflect data for all isoforms of that 1683 
protein. Abundantly expressed prey may be more easily validated using IB with antibodies 1684 
against an endogenous protein; less abundant proteins may require overexpression to enable 1685 
detection. (C) All detected interacting proteins for each bait, without filtering. 1686 
 1687 
Supplementary File 3. Validation of the interactome data from BioGRID, IntAct, Uniprot, 1688 
MINT and Virus Mentha (Calderone et al., 2015; Chatr-Aryamontri et al., 2013; Licata et al., 1689 
2012; Orchard et al., 2014). Columns give details of the database(s) that included each 1690 
interaction, the method used, and cell type employed. Interactome scores from the present 1691 
study are shown in columns H-K. Column L shows whether a given interaction was validated 1692 
in this interactome. A value of 1 indicates validation; 0 indicates detection of the interaction 1693 
but failure to pass stringent scoring thresholds; ‘ND’ indicates the interaction was not 1694 
detected by the interactome. Column M shows the ranked abundance of each human prey 1695 
protein from Supplementary File 1C. Interactions that were not detected in this study 1696 
included a number of prey proteins that could not be detected in HFFFs. Further details are 1697 
given in the Materials and Methods section. 1698 
 1699 
Supplementary File 4. Enriched functional pathways, protein components and interacting 1700 
viral baits. (A) All enriched functional pathways amongst all human HCIPs (p<0.05, after 1701 
Benjamini-Hochberg adjustment). Column D shows the bait(s) interacting with each pathway 1702 
component. (B) Further details of viral baits interacting with components of each pathway. 1703 
Two values are shown: “% interaction”, the percentage of human interactors of each bait that 1704 
belonged to the pathway (relates to Figure 2, where viral baits are included if >33% of 1705 
interactors belonged to a given pathway). “% function” illustrates the percentage of proteins 1706 
from the pathway that interacted with the bait (relates to Figure 2 – Figure Supplement 1, 1707 
where viral baits are included if >33% of the pathway components identified interacted with a 1708 
given viral bait). Values of >33% are coloured in this table. The ‘count’ column shows the 1709 
total number of interacting pathway members; Figures 2 and Figure 2 – Figure Supplement 1710 
1 included data with counts ≥2. (C) All enriched functional pathways amongst human HCIPs 1711 
from each temporal class (p<0.05, after Benjamini-Hochberg adjustment). Column E shows 1712 
the bait(s) interacting with each pathway component. This data underlies Figure 2 – Figure 1713 
Supplement 2A. (D) Temporal interactions of viral bait and viral prey proteins. This data 1714 
underlies Figure 2 – Figure Supplement 2B. 1715 
 1716 
Supplementary File 5. Full data underlying the domain-domain association predictions. (A) 1717 
HCMV proteins that contain each described Pfam domain. Links are given to additional 1718 
information on each domain on the Pfam website. Overall 96 domains have been identified in 1719 
HCMV proteins by Pfam, however only 10 domains were identified in two or more baits. 1720 
Only this subset was examined to increase confidence in domain association predictions. (B) 1721 
Subset of Supplementary File 2B illustrating individual protein-protein interactions that 1722 
underpin data shown in Figure 4A. 1723 
 1724 
Supplementary File 6. Proteins degraded early during HCMV infection from (Nightingale et 1725 
al., 2018), using sensitive criteria. Interactome data identified viral baits for 31 of these 1726 
degraded proteins. 1727 
 1728 
Supplementary File 7. Enrichment of functional pathways among proteins interacting with 1729 
(A) ORFL147C, using DAVID software and a maximum p-value of 0.3; (B) ORFL147C, 1730 
using the Reactome database and ≥4 entities per enriched pathway; (C) both HCMV and 1731 
KSHV (Davis et al., 2015), using DAVID software and a maximum p-value of 0.05; (D) only 1732 
HCMV as described in Figure 5C, using DAVID software and a maximum p-value of 0.01. 1733 
 1734 
SOURCE FILES PROVIDED 1735 
 1736 
Figure 1 Figure Supplement 1 - source data 1: Correlation of the number of total, unique 1737 
and bait peptides from each protein identified in replicates 1 and 2. 1738 
Figure 1 Figure Supplement 1 - source data 2: Reproducibility of interactome analyses. 1739 
Figure 6 - source data 1: Growth analysis of an ORFL147C-deficient recombinant. 1740 
Figure 6 - source data 2: Tandem mass tag-based proteomics analysis of ORFL147C protein 1741 
expression. 1742 
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